Substituted quinazoline compounds useful as T cell activators

By developing substituted quinazolinyl compounds as DGKα and DGKζ inhibitors, the problem of inhibition of anti-tumor immunity in the prior art has been solved, and T cell activation and anti-tumor function have been enhanced for the treatment of cancer and viruses Infect.

CN114846007BActive Publication Date: 2024-11-22BRISTOL MYERS SQUIBB CO
View PDF 23 Cites 0 Cited by

Patent Information

Application Number
CN202080089197.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-12-23
Filing Date
2020-12-22
Publication Date
2024-11-22
Estimated Expiration
2040-12-22

AI Technical Summary

Technical Problem

The prior art is difficult to effectively inhibit the activity of diacylglycerol kinase (DGK)α and ζ, resulting in inhibition of anti-tumor immunity and lack of compounds with selective inhibitors.

Method used

A substituted quinazolinyl compound was developed as an inhibitor of DGKα and DGKζ to enhance T cell activation and anti-tumor function, with stability, bioavailability and low toxicity values.

Benefits of technology

These compounds can safely and effectively inhibit DGKα and DGKζ, restore T cell signaling, lower antigen thresholds, enhance antitumor function, and are used to treat cancer and viral infections.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114846007B_ABST
    Figure CN114846007B_ABST
Patent Text Reader

Abstract

Disclosed are compounds of formula (I): (I) or a salt thereof, wherein R 1 , R 2 , R 4 , R 5 , R 6 and m are defined herein. Also disclosed are methods of using such compounds to inhibit the activity of one or both of diacylglycerol kinase alpha (DGKα) and diacylglycerol kinase zeta (DGKζ) and pharmaceutical compositions comprising such compounds. These compounds can be used to treat viral infections and proliferative disorders, such as cancer. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Cross-references

[0002] This application claims the benefit of Indian Provisional Application No. 201911053553 filed on December 23, 2019, which is incorporated herein in its entirety.

[0003] manual

[0004] The present invention generally relates to substituted quinazoline compounds that activate T cells, promote T cell proliferation and / or exhibit anti-tumor activity. Substituted quinazoline compounds, compositions comprising such compounds, and methods of use thereof are provided herein. The present invention further relates to pharmaceutical compositions comprising at least one compound according to the present invention, which can be used to treat proliferative disorders (such as cancer) and viral infections. Background Art

[0005] Human cancers have many genetic and epigenetic changes, producing new antigens that are potentially recognizable by the immune system (Sjoblom et al., (2006) Science 314: 268-74). The adaptive immune system, composed of T lymphocytes and B lymphocytes, has a strong anti-cancer potential, with a wide range of capabilities and precise specificity to respond to diverse tumor antigens. In addition, the immune system exhibits considerable plasticity and memory components. Successfully utilizing all these properties of the adaptive immune system will make immunotherapy unique among all cancer treatments. However, although endogenous immune responses to cancer have been observed in preclinical models and patients, this response is ineffective, and confirmed cancers are considered "self" and tolerated by the immune system. Tumors that contribute to this state of tolerance may actively destroy anti-tumor immunity using several different mechanisms. These mechanisms include dysfunctional T cell signaling (Mizoguchi et al., (1992) Science 258:1795-98), inhibitory regulatory cells (Facciabene et al., (2012) Cancer Res. 72:2162-71), and the deployment of endogenous "immune checkpoints" that serve to downregulate the magnitude of the adaptive immune response and protect normal tissues from collateral damage by tumors to evade immune destruction (Topalian et al., (2012) Curr. Opin. Immunol. 24:1-6; Mellman et al. (2011) Nature 480:480-489).

[0006] Diacylglycerol kinase (DGK) is a lipid kinase that mediates the conversion of diacylglycerol to phosphatidic acid to terminate the T cell function propagated by the TCR signal transduction pathway. Therefore, DGK is used as an intracellular checkpoint, and inhibition of DGK is expected to enhance T cell signal transduction pathways and T cell activation. Supportive evidence includes knockout mouse models of DGKα or DGKζ that show a highly reactive T cell phenotype and improved anti-tumor immune activity (Riese MJ et al., Journal of Biological Chemistry, (2011) 7: 5254-5265; Zha Y et al., Nature Immunology, (2006) 12: 1343; Olenchock BA et al., (2006) 11: 1174-81). Furthermore, tumor-infiltrating lymphocytes isolated from human renal cell carcinoma patients were observed to overexpress DGKa, which resulted in suppressed T cell function (Prinz, PU et al., J Immunology (2012) 12:5990-6000). Therefore, DGKα and DGKζ are considered targets for cancer immunotherapy (Riese M.J. et al., Front Cell Dev Biol. (2016) 4:108; Chen, SS et al., Front Cell Dev Biol. (2016) 4:130; Avila-Flores; A. et al., Immunology and Cell Biology (2017) 95:549-563; Noessner, E., Front Cell Dev Biol. (2017) 5:16; Krishna, S. et al., Front Immunology (2013) 4:178; Jing, W. et al., Cancer Research (2017) 77:5676-5686).

[0007] There remains a need for compounds that are useful as inhibitors of one or both of DGKα and DGKζ. In addition, there remains a need for compounds that are useful as inhibitors of one or both of DGKα and DGKζ that have selectivity relative to other diacylglycerol kinases, protein kinases, and / or other lipid kinases.

[0008] Therefore, safe and effective agents that restore T cell activation, lower antigenic thresholds, enhance anti-tumor function, and / or overcome the inhibitory effects of one or more endogenous immune checkpoints (such as PD-1, LAG-3, and TGFβ) would be an important addition to the treatment of patients with proliferative disorders (such as cancer) as well as viral infections. Summary of the invention

[0009] Applicants have discovered compounds that are active as inhibitors of one or both of DGKα and DGKζ. In addition, applicants have discovered compounds that are active as inhibitors of one or both of DGKα and DGKζ and have selectivity relative to other diacylglycerol kinases, protein kinases, and / or other lipid kinases. These compounds are provided for use as medicaments having desirable stability, bioavailability, therapeutic index, and toxicity values ​​that are important for their pharmaceutical use.

[0010] The present invention provides substituted quinazolinyl compounds of formula (I) useful as inhibitors of DGKα, DGKζ, or both DGKα and DGKζ, including salts and prodrugs thereof.

[0011] The present invention also provides a pharmaceutical composition comprising a compound of formula (I) and / or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

[0012] The present invention also provides a method for treating a disease or disorder associated with the activity of DGKα, DGKζ, or both DGKα and DGKζ, comprising administering a compound of formula (I) and / or a pharmaceutically acceptable salt thereof to a mammalian patient.

[0013] The present invention also provides methods and intermediates for preparing the compound of formula (I) and / or its salt.

[0014] The present invention also provides a compound of formula (I) and / or a pharmaceutically acceptable salt thereof for use in therapy.

[0015] The present invention also provides the use of a compound of formula (I) and / or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for treating proliferative disorders such as cancer and viral infection.

[0016] The compounds of formula (I) and compositions comprising the compounds of formula (I) can be used to treat, prevent or cure viral infections and various proliferative disorders, such as cancer. Pharmaceutical compositions comprising these compounds can be used to treat, prevent or slow down the progression of diseases or disorders (such as viral infections and cancer) in a variety of therapeutic areas.

[0017] These and other features of the present invention will be set forth in expanded form as the disclosure proceeds. DETAILED DESCRIPTION

[0018] The first aspect of the present invention provides at least one compound of formula (I):

[0019]

[0020] or a salt thereof, wherein:

[0021] R1 is H, F, Cl, Br, -CN, zero to four R 1a Substituted C 1-3 Alkyl, with zero to four R 1a Substituted C 3-4 Cycloalkyl, 0 to 4 R 1a Substituted C 1-3 Alkoxy, -C(O)NR a R a 、-NR a R a 、-S(O) n R e , or -P(O)R e R e ;

[0022] Each R 1a are independently F, Cl, -CN, -OH, -OCH3, or -NR a R a ;

[0023] Each R a independently H or C 1-3 alkyl;

[0024] Each R e Independently C 3-4 Cycloalkyl or 0 to 4 R 1a Substituted C 1-3 alkyl;

[0025] R2 is H, zero to 4 R 2a Substituted C 1-3 Alkyl, with zero to four R 2a Substituted C 2-3 alkenyl, or 0 to 4 R 2a Substituted C 3-4 Cycloalkyl;

[0026] Each R 2a are independently F, Cl, -CN, -OH, -O(C 1-2 Alkyl), C 3-4 Cycloalkyl, C 3-4 Alkenyl, or C 3-4 Alkynyl;

[0027] R4 is -CH2R 4a 、-CH2CH2R 4a 、-CH2CHR 4a R 4d 、-CHR 4a R 4b , or -CR 4a R 4b R 4c ;

[0028] R 4a and R 4b Independently are:

[0029] (i) C substituted with zero to four substituents independently selected from the following 1-6 Alkyl: F, Cl, -CN, -OH, -OCH3, -SCH3, C 1-3 Fluoroalkoxy, -NR a R a 、-S(O)2R e , or -NR a S(O)2R e ;

[0030] (ii)C 3-6 Cycloalkyl, heterocyclyl, phenyl, or heteroaryl, each substituted with zero to four substituents independently selected from the group consisting of F, Cl, Br, -CN, -OH, C 1-6 Alkyl, C 1-3 Fluoroalkyl, C 1-4 Hydroxyalkyl, -(CH2) 1-2 O(C 1-3 Alkyl), C 1-4 Alkoxy, -O(C 1-4 Hydroxyalkyl), -O(CH) 1-3 O(C 1-3 Alkyl), C 1-3 Fluoroalkoxy, -O(CH) 1-3 NR c R c , -OCH2CH=CH2, -OCH2C≡CH, -C(O)(C 1-4 alkyl), -C(O)OH, -C(O)O(C 1-4 Alkyl), -NR c R c 、-NR a S(O)2(C 1-3 Alkyl), -NR a C(O)(C 1-3 Alkyl), -NR a C(O)O(C 1-4 alkyl), -P(O)(C 1-3 Alkyl)2, -S(O)2(C 1-3 Alkyl), -O(CH2) 1-2 (C 3-6 Cycloalkyl), -O(CH2) 1-2(morpholinyl), cyclopropyl, cyanocyclopropyl, methylazetidinyl, acetylazetidinyl, (tert-butoxycarbonyl)azetidinyl, triazolyl, tetrahydropyranyl, morpholinyl, thienyl, methylpiperidinyl, and R d ;or

[0031] (iii) C substituted with a cyclic group selected from the following 1-4 Alkyl: C 3-6 Cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the cyclic group is substituted by zero to three substituents independently selected from the group consisting of F, Cl, Br, -OH, -CN, C 1-6 Alkyl, C 1-3 Fluoroalkyl, C 1-3 Alkoxy, C 1-3 Fluoroalkoxy, -OCH2CH=CH2, -OCH2C≡CH, -NR c R c 、-NR a S(O)2(C 1-3 Alkyl), -NR a C(O)(C 1-3 Alkyl), -NR a C(O)O(C 1-4 alkyl), and C 3-6 Cycloalkyl;

[0032] or R 4a and R 4b Together with the carbon atom to which they are attached, they form C 3-6 Cycloalkyl or 3 to 6 membered heterocyclic group, each of which is substituted by zero to three R f replace;

[0033] Each R f are independently F, Cl, Br, -OH, -CN, C 1-6 Alkyl, C 1-3 Fluoroalkyl, C 1-3 Alkoxy, C 1-3 Fluoroalkoxy, -OCH2CH=CH2, -OCH2C≡CH, -NR c R c , or a cyclic group selected from the following: C 3-6 Cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, monocyclic heteroaryl, and bicyclic heteroaryl, each cyclic group being substituted by zero to three substituents independently selected from the group consisting of F, Cl, Br, -OH, -CN, C 1-6 Alkyl, C 1-3 Fluoroalkyl, C 1-3 Alkoxy, C 1-3 Fluoroalkoxy, and -NR c R c ;

[0034] R 4c It is C 1-6 Alkyl or C 3-6 cycloalkyl, each substituted by zero to 4 substituents independently selected from the group consisting of F, Cl, -OH, C 1-2 Alkoxy, C 1-2 Fluoroalkoxy, and -CN;

[0035] R 4d is -OCH3;

[0036] Each R c independently H or C 1-2 alkyl;

[0037] R d is phenyl substituted with zero to one substituent selected from the group consisting of F, Cl, -CN, -CH3, and -OCH3;

[0038] Each R5 is independently F, Cl, -CN, -OH, or any of zero to four R g Substituted C 1-6 Alkyl, with zero to four R g Substituted C 1-3 Alkoxy, with zero to four R g Substituted C 2-4 Alkenyl, 0 to 4 R g Substituted C 2-4 Alkynyl, 0 to 4 R g Substituted C 3-4 Cycloalkyl, 0 to 4 R g Substituted phenyl, 0 to 3 R g Substituted oxadiazole, substituted with zero to four R g Substituted pyridyl, -(CH2) 1-2 (zero to 4 R g substituted heterocyclic group), -(CH2) 1-2 NR c C(O)(C 1-4 Alkyl), -(CH2) 1-2 NR c C(O)O(C 1-4 Alkyl), -(CH2) 1-2 NR c S(O)2(C 1-4 alkyl), -C(O)(C 1-4 alkyl), -C(O)OH, -C(O)O(C 1-4 alkyl), -C(O)O(C 3-4 Cycloalkyl), -C(O)NR a R a, or -C(O)NR a (C 3-4 cycloalkyl), or two R5 attached to the same carbon atom form =0;

[0039] Each R g are independently F, Cl, -CN, -OH, C 1-3 Alkoxy, C 1-3 Fluoroalkoxy, -O(CH2) 1-2 O(C 1-2 Alkyl), C 3-5 Cycloalkyl, or -NR c R c ;

[0040] each R6 is H, F, Cl, -CN, -CH3, -CH2F, -CHF2, -CF3, or -OCH3;

[0041] m is zero, 1, 2, or 3; and

[0042] n is zero, 1, or 2.

[0043] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein: R1 is H, F, Cl, Br, -CN, 0 to 4 R 1a Substituted C 1-3 Alkyl, 0 to 3 R 1a Substituted cyclopropyl, substituted by zero to three R 1a Substituted C 1-3 Alkoxy, -C(O)NR a R a 、-NR a R a 、-S(O) n CH3, or -P(O)(CH3)2; each R 1a is independently F, Cl, or -CN; each R a independently H or C 1-3 Alkyl; R2 is H, with zero to two R 2a Substituted C 1-2 Alkyl, or zero to two R 2a Substituted C 2-3 alkenyl; each R 2a are independently F, Cl, -CN, -OH, -O(C 1-2 alkyl), cyclopropyl, C 3-4 Alkenyl, or C 3-4 Alkynyl; R 4a and R 4b are independently: (i) C substituted with zero to four substituents independently selected from the following 1-4Alkyl: F, Cl, -CN, -OH, -OCH3, -SCH3, C 1-3 Fluoroalkoxy, and -NR a R a ; (ii) C 3-6 Cycloalkyl, heterocyclyl, phenyl, or heteroaryl, each substituted with zero to four substituents independently selected from the group consisting of F, Cl, Br, -CN, -OH, C 1-6 Alkyl, C 1-3 Fluoroalkyl, -CH2OH, -(CH2) 1-2 O(C 1-2 Alkyl), C 1-4 Alkoxy, -O(C 1-4 Hydroxyalkyl), -O(CH) 1-2 O(C 1-2 Alkyl), C 1-3 Fluoroalkoxy, -O(CH) 1-2 NR c R c , -OCH2CH=CH2, -OCH2C≡CH, -C(O)(C 1-4 alkyl), -C(O)OH, -C(O)O(C 1-4 Alkyl), -NR c R c 、-NR a S(O)2(C 1-3 Alkyl), -NR a C(O)(C 1-3 Alkyl), -NR a C(O)O(C 1-4 alkyl), -P(O)(C 1-2 Alkyl)2, -S(O)2(C 1-3 Alkyl), -O(CH2) 1-2 (C 3-4 Cycloalkyl), -O(CH2) 1-2 (morpholinyl), cyclopropyl, cyanocyclopropyl, methylazetidinyl, acetylazetidinyl, (tert-butoxycarbonyl)azetidinyl, triazolyl, tetrahydropyranyl, morpholinyl, thienyl, methylpiperidinyl, and R d or (iii) C substituted by a cyclic group selected from 1-3 Alkyl: C 3-6 Cycloalkyl, heterocyclyl, phenyl, and heteroaryl, wherein the cyclic group is substituted by zero to three substituents independently selected from the group consisting of F, Cl, Br, -OH, -CN, C 1-3 Alkyl, C 1-2 Fluoroalkyl, C 1-3 Alkoxy, C 1-2Fluoroalkoxy, -OCH2CH=CH2, -OCH2C≡CH, -NR c R c 、-NR a S(O)2(C 1-3 Alkyl), -NR a C(O)(C 1-3 Alkyl), -NR a C(O)O(C 1-4 alkyl), and C 3-4 Cycloalkyl; or R 4a and R 4b Together with the carbon atom to which they are attached, they form C 3-6 Cycloalkyl or 3 to 6 membered heterocyclic group, each of which is substituted by zero to three R f Replace; each R f are independently F, Cl, Br, -OH, -CN, C 1-4 Alkyl, C 1-2 Fluoroalkyl, C 1-3 Alkoxy, C 1-2 Fluoroalkoxy, -OCH2CH=CH2, -OCH2C≡CH, -NR c R c , or a cyclic group selected from the following: C 3-6 Cycloalkyl, 3- to 6-membered heterocyclyl, phenyl, monocyclic heteroaryl, and bicyclic heteroaryl, each cyclic group being substituted by zero to three substituents independently selected from the group consisting of F, Cl, Br, -OH, -CN, C 1-4 Alkyl, C 1-2 Fluoroalkyl, C 1-3 Alkoxy, C 1-2 Fluoroalkoxy, and -NR c R c ; R 4c It is C 1-4 Alkyl or C 3-6 cycloalkyl, each substituted by zero to 4 substituents independently selected from the group consisting of F, Cl, -OH, C 1-2 Alkoxy, C 1-2 fluoroalkoxy, and -CN; each R5 is independently F, -CN, -OH, zero to four R g Substituted C 1-5 Alkyl, 0 to 3 R g Substituted C 1-2 Alkoxy, with zero to four R g Substituted C 2-3 Alkenyl, 0 to 4 R g Substituted C 2-3 Alkynyl, 0 to 4 R g Substituted C 3-4 Cycloalkyl, 0 to 3 Rg Substituted phenyl, 0 to 3 R g Substituted oxadiazole, substituted by zero to three R g Substituted pyridyl, -(CH2) 1-2 (zero to 4 R g substituted heterocyclic group), -(CH2) 1-2 NR c C(O)(C 1-4 Alkyl), -(CH2) 1-2 NR c C(O)O(C 1-4 Alkyl), -(CH2) 1-2 NR c S(O)2(C 1-4 alkyl), -C(O)(C 1-4 alkyl), -C(O)OH, -C(O)O(C 1-4 alkyl), -C(O)O(C 3-4 Cycloalkyl), -C(O)NR a R a , or -C(O)NR a (C 3-4 cycloalkyl), or two R5 attached to the same carbon atom form =0; each R6 is H, F, or -CH3; and m is zero, 1, 2, or 3.

[0044] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein: R1 is H, F, -CN, or -OCH3; R2 is H, -CH3, -CH2CN, -CH2CH2F, or -CH2CH=CH2; R4 is -CH2R 4a or -CHR 4a R 4b ; R 4a is phenyl, naphthyl, or indolyl, each substituted with zero to two substituents independently selected from the group consisting of F, -CH3, -CH2CH3, and -OCH3; R 4b is phenyl or fluorophenyl; each R5 is -CH3, or two R5 attached to the same carbon atom form =0; and m is zero, 1 or 2.

[0045] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R1 is H, F, Cl, Br, -CN, substituted by zero to four R 1a Substituted C 1-3 Alkyl, 0 to 3 R 1a Substituted cyclopropyl, substituted by zero to three R 1a Substituted C 1-3 Alkoxy, -C(O)NR a R a、-NR a R a 、-S(O) n CH3, or -P(O)(CH3)2. Included in this embodiment are compounds wherein R1 is H, F, Cl, Br, -CN, -CH3, -CHF2, -CF3, cyclopropyl, or -OCH3. Also included in this embodiment are compounds wherein R1 is H, F, -CN, or -OCH3.

[0046] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R2 is H, substituted by zero to two R 2a Substituted C 1-2 Alkyl, or zero to two R 2a Substituted C 2-3 This embodiment includes compounds wherein R2 is H, -CH3, -CH2CN, -CH2CH2F, or -CH2CH=CH2. This embodiment also includes compounds wherein R2 is H, -CH3, -CH2CN, or -CH2CH2F.

[0047] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is -CH2R 4a or -CH2CH2R 4a This embodiment includes compounds wherein R4 is -CH2R 4a or-CD2R 4a .

[0048] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is -CH2R 4a This embodiment includes compounds wherein R4 is -CD2R 4a .

[0049] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is -CHR 4a R 4b or -CR 4a R 4b R 4c .

[0050] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is -CHR 4a R 4b .

[0051] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is -CH2R 4a or -CHR 4a R 4b.

[0052] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein m is 1, 2 or 3; and each R5 is independently F, -CN, -OH, substituted by zero to 4 R g Substituted C 1-5 Alkyl, 0 to 3 R g Substituted C 1-2 Alkoxy, with zero to four R g Substituted C 2-3 Alkenyl, 0 to 4 R g Substituted C 2-3 Alkynyl, 0 to 4 R g Substituted C 3-4 Cycloalkyl, 0 to 3 R g Substituted phenyl, 0 to 3 R g Substituted oxadiazole, substituted by zero to three R g Substituted pyridyl, -(CH2) 1-2 (zero to 4 R g substituted heterocyclic group), -(CH2) 1-2 NR c C(O)(C 1-4 Alkyl), -(CH2) 1-2 NR c C(O)O(C 1-4 Alkyl), -(CH2) 1-2 NR c S(O)2(C 1-4 alkyl), -C(O)(C 1-4 alkyl), -C(O)OH, -C(O)O(C 1-4 alkyl), -C(O)O(C 3-4 Cycloalkyl), -C(O)NR a R a , or -C(O)NR a (C 3-4 cycloalkyl), or two R5 attached to the same carbon atom form =0. This embodiment includes compounds wherein each R5 is independently F, -CN, -OH, g Substituted C 1-2 Alkyl, 0 to 3 R g Substituted C 1-2 Alkoxy, with zero to two R g Substituted C 3-4 Cycloalkyl, -C(O)(C 1-4 alkyl), -C(O)OH, -C(O)O(C 1-2 alkyl), or -C(O)NR a R a, or two R5 attached to the same carbon atom form =0. Also included in this embodiment are compounds wherein each R5 is -CH3, or two R5 attached to the same carbon atom form =0.

[0053] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein m is 2 and two R5 are attached to the same carbon atom to form =0.

[0054] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein m is zero.

[0055] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein m is 1, 2 or 3. Included in this embodiment are compounds wherein m is 1 or 2. Also included in this embodiment are compounds wherein m is 1.

[0056] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein m is 2 or 3. Included in this embodiment is a compound wherein m is 2.

[0057] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein m is 3.

[0058] In one embodiment, a compound of formula (I) or a salt thereof is provided, which has the structure of formula (II):

[0059]

[0060] Where R 5a , R 5b , R 5c and R 5d One, two or three of them are each R5, and R 5a , R 5b , R 5c and R 5d In this embodiment, the rest are each hydrogen. Such compounds are included, wherein each R is independently-CN,-CH,-CHCH,-CH(CH),-CHC(CH),-CHF,-C(CH)F,-CF(CH)CH(CH),-CHOH,-C(CH)OH,-C(CH)(OH)CH(CH),-CHOCH,-C(O)C(CH),-C(O)OH,-C(O)OCH,-C(O)OC(CH),-C(O)NH,-C(O)NH(cyclopropyl),-C(O)O(cyclopropyl), cyclopropyl, phenyl, methyloxadiazolyl, or picoline.

[0061] In one embodiment, a compound of formula (I) or a salt thereof is provided, which has the structure of formula (III):

[0062]

[0063] In one embodiment, a compound of formula (III) or a salt thereof is provided, wherein R 5a is -CH3 and R 5c It is -CH3.

[0064] In one embodiment, a compound of formula (III) or a salt thereof is provided, wherein R 5a is -CH3 and R 5c It is -CH2CH3.

[0065] In one embodiment, a compound of formula (III) or a salt thereof is provided, wherein R 5a is -CH2CH3 and R 5c It is -CH3.

[0066] In one embodiment, a compound of formula (III) or a salt thereof is provided, wherein R 5a is -CH2CH3 and R 5c It is -CH2CH3.

[0067] In one embodiment, a compound of formula (III) or a salt thereof is provided, wherein R 5a is -CH3 and R 5c It is -CH2OH.

[0068] In one embodiment, a compound of formula (III) or a salt thereof is provided, wherein R 5a is -CH3 and R 5c It is -CH2OCH3.

[0069] In one embodiment, a compound of formula (I) or a salt thereof is provided, which has the following structure:

[0070]

[0071] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is:

[0072]

[0073]

[0074] Included within this embodiment are compounds wherein R1 is H, Br, -CN, or -OCH3; and R2 is -CH3.

[0075] In one embodiment, a compound of formula (I) or a salt thereof is provided, wherein R4 is:

[0076] Included in this embodiment are compounds wherein R1 is H, Br, -CN, or -OCH3; and R2 is -CH3. Also included in this embodiment are compounds wherein R1 is -CN; and R2 is -CH3.

[0077] The present invention can be implemented in other specific forms without departing from its spirit or basic attributes. The present invention encompasses all combinations of aspects of the present invention described herein and / or embodiments. It should be understood that any and all embodiments of the present invention can be combined with any one or more other embodiments to describe other embodiments. It should also be understood that each individual element in these embodiments is intended to be combined with any and all other elements from any embodiment to describe other embodiments.

[0078] definition

[0079] Those skilled in the art can more easily understand the features and advantages of the present invention after reading the following detailed description. It should be understood that, for clear reasons, some features of the present invention described in the context of a separate embodiment may also be combined to form a single embodiment. On the contrary, for reasons of simplicity, the various features of the present invention described in the context of a single embodiment may also be combined to form its sub-combination. It is intended that the embodiments identified as exemplary or preferred herein are illustrative and not restrictive.

[0080] Unless otherwise clearly stated herein, references made in the singular may also include the plural form. For example, "a / an" may refer to one / an, or one or more / one or more.

[0081] As used herein, the phrase "compound and / or its salt" refers to at least one compound, at least one salt of the compound, or a combination thereof. For example, the compound of formula (I) and / or its salt includes a compound of formula (I); two compounds of formula (I); a salt of a compound of formula (I); a compound of formula (I) and one or more salts of a compound of formula (I); and two or more salts of a compound of formula (I).

[0082] Unless otherwise indicated, any atom with unsatisfied valences is assumed to have sufficient hydrogen atoms to satisfy the valences.

[0083] The definitions set forth herein take precedence over definitions set forth in any patent, patent application, and / or patent application publication incorporated herein by reference.

[0084] Listed below are definitions of various terms used to describe the present invention. These definitions apply to the terms as they are used throughout the specification, either individually or as part of a larger group (unless they are otherwise limited in specific instances).

[0085] Throughout the specification, one skilled in the art can select groups and substituents thereof to provide stable moieties and compounds.

[0086]

[0087] to delineate the bond that is the point of attachment of a moiety or substituent to the core or backbone structure.

[0088] The terms "halo" and "halogen" as used herein refer to F, Cl, Br and I.

[0089] The term "cyano" refers to a -CN group.

[0090] The term "amino" refers to a -NH2 group.

[0091] The term "oxo" refers to a =0 group.

[0092] As used herein, the term "alkyl" refers to both branched and straight-chain saturated aliphatic hydrocarbon groups containing, for example, from 1 to 12 carbon atoms, from 1 to 6 carbon atoms, and from 1 to 4 carbon atoms. Examples of alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (e.g., n-propyl and isopropyl), butyl (e.g., n-butyl, isobutyl, sec-butyl, and tert-butyl), and pentyl (e.g., n-pentyl, isopentyl, neopentyl), n-hexyl, 2-methylpentyl, 2-ethylbutyl, 3-methylpentyl, and 4-methylpentyl. When a number appears in a subscript after the symbol "C", the subscript more specifically defines the number of carbon atoms that a particular group may contain. For example, "C 1-4 "Alkyl" refers to straight and branched chain alkyl groups having one to four carbon atoms.

[0093] As used herein, the term "fluoroalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups substituted with one or more fluorine atoms. 1-4 "Fluoroalkyl" is intended to include C1, C2, C3 and C4 alkyl groups substituted with one or more fluorine atoms. Representative examples of fluoroalkyl groups include, but are not limited to, -CF3 and -CH2CF3.

[0094] The term "hydroxyalkyl" includes both branched and straight chain saturated alkyl groups substituted with one or more hydroxy groups. For example, "hydroxyalkyl" includes -CH2OH, -CH2CH2OH, and C 1-4 Hydroxyalkyl.

[0095] The term "alkenyl" refers to a straight or branched chain hydrocarbon group containing from 2 to 12 carbon atoms and at least one carbon-carbon double bond. Exemplary such groups include vinyl or allyl. For example, "C 2_6 "Alkenyl" refers to straight-chain and branched alkenyl groups having two to six carbon atoms.

[0096] The term "alkynyl" refers to a straight or branched chain hydrocarbon group containing from 2 to 12 carbon atoms and at least one carbon to carbon triple bond. Exemplary such groups include ethynyl. For example, "C 2_6 "Alkynyl" refers to straight-chain and branched alkynyl groups having two to six carbon atoms.

[0097] As used herein, the term "cycloalkyl" refers to a group derived from a non-aromatic monocyclic or polycyclic hydrocarbon molecule by removing a hydrogen atom from a saturated ring carbon atom. Representative examples of cycloalkyls include, but are not limited to, cyclopropyl, cyclopentyl, and cyclohexyl. When a number appears in a subscript position after the symbol "C", the subscript more specifically defines the number of carbon atoms that a particular cycloalkyl may contain. For example, "C 3-6 "Cycloalkyl" means a cycloalkyl group having three to six carbon atoms.

[0098] As used herein, the term "fluorocycloalkyl" is intended to include cycloalkyl groups substituted with one or more fluorine atoms.

[0099] As used herein, the term "alkoxy" refers to an alkyl group attached to the parent molecular moiety through an oxygen atom, such as methoxy (-OCH3). For example, "C 1-3 The "alkoxy group" refers to an alkoxy group having 1 to 3 carbon atoms.

[0100] The terms "fluoroalkoxy" and "-O(fluoroalkyl)" refer to a fluoroalkyl group as defined above attached through an oxygen bond (-O-). 1-4 "Fluoroalkoxy" is intended to include C1, C2, C3 and C4 fluoroalkoxy.

[0101] The terms "carbocyclo," "carbocyclic," or "carbocyclyl" are used interchangeably and refer to a cyclic group having at least one saturated or partially saturated non-aromatic ring in which all atoms of all rings are carbon. The carbocyclyl ring may be unsubstituted or may contain one or more substituents where valence permits. Thus, the term includes non-aromatic rings such as, for example, cycloalkyl, cycloalkenyl, and cycloalkynyl rings. Exemplary bicyclic carbocyclyls include indanyl, indenyl, dihydronaphthyl, tetrahydronaphthyl, hexahydronaphthyl, octahydronaphthyl, decahydronaphthyl, bicycloheptyl, bicyclooctyl, and bicyclononyl.

[0102] As used herein, the term "aryl" refers to a group of atoms derived from a molecule containing one or more aromatic rings by removing one hydrogen bonded to the aromatic rings. Representative examples of aryl include, but are not limited to, phenyl and naphthyl. Aryl rings may be unsubstituted or may contain one or more substituents where valence permits.

[0103] As used herein, the term "benzyl" refers to a methyl group in which one hydrogen atom is replaced by a phenyl group. The phenyl ring may be unsubstituted or may contain one or more substituents as valence permits.

[0104] The term "heteroatom" refers to oxygen (O), sulfur (S) and nitrogen (N).

[0105] The terms "heterocycle", "heterocyclic" or "heterocyclyl" are used interchangeably and refer to a cyclic group having at least one saturated or partially saturated non-aromatic ring and wherein one or more rings have at least one heteroatom (O, S or N), preferably 1 to 3 heteroatoms independently selected from O, S and / or N. The rings of such heteroatom-containing groups may contain one or two oxygen atoms or sulfur atoms and / or one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less, and further provided that the ring contains at least one carbon atom. The nitrogen and sulfur atoms may be optionally oxidized, and the nitrogen atom may be optionally quaternized. The heterocyclic group may be attached to any available nitrogen or carbon atom. The heterocyclic ring may be unsubstituted or may contain one or more substituents where valence permits.

[0106] Exemplary monocyclic heterocyclyls include pyrrolidinyl, imidazolinyl, oxazolidinyl, isoxazolyl, tetrahydrothiazolyl, isotetrahydrothiazolyl, tetrahydrofuranyl, piperidinyl, piperazinyl, 2-oxopiperazinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl, 4-piperidonyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone, 1,3-dioxolane, tetrahydro-1,1-dioxothiphenyl, dihydroisoindolyl, and tetrahydroquinolinyl.

[0107] The term "heteroaryl" refers to substituted and unsubstituted aromatic 5 or 6-membered monocyclic groups and 9 or 10-membered bicyclic groups having at least one heteroatom (O, S or N) in at least one ring, the heteroatom-containing ring preferably having 1, 2 or 3 heteroatoms independently selected from O, S and / or N. Each ring of the heteroaryl containing heteroatoms may contain one or two oxygen or sulfur atoms and / or from one to four nitrogen atoms, provided that the total number of heteroatoms in each ring is four or less and each ring has at least one carbon atom. The fused rings constituting the bicyclic group are aromatic and may contain only carbon atoms. The nitrogen and sulfur atoms may optionally be oxidized, and the nitrogen atom may optionally be quaternized. The bicyclic heteroaryl must contain only aromatic rings. The heteroaryl group may be attached to any available nitrogen or carbon atom of any ring. The heteroaryl ring system may be unsubstituted or may contain one or more substituents.

[0108] Exemplary monocyclic heteroaryl groups include pyrrolyl, pyrazolyl, pyrazolinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, isothiazolyl, furanyl, thienyl, oxadiazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, and triazinyl.

[0109] Exemplary bicyclic heteroaryl groups include indolyl, benzothiazolyl, benzodioxolyl, benzoxazolyl, benzothiophenyl, quinolinyl, tetrahydroisoquinolinyl, isoquinolinyl, benzimidazolyl, benzopyranyl, indolizinyl, benzofuranyl, chromonyl, coumarinyl, benzopyranyl, cinnolinyl, quinoxalinyl, indazolyl, and pyrrolopyridinyl.

[0110] The phrase "pharmaceutically acceptable" is used herein to refer to those compounds, materials, compositions, and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problem or complication, commensurate with a reasonable benefit / risk ratio.

[0111] The compound of formula (I) can form salts, which are also within the scope of the present invention. Unless otherwise indicated, reference to the compounds of the present invention should be understood to include reference to one or more salts thereof. The term "one or more salts" refers to acidic and / or basic salts formed with inorganic and / or organic acids and bases. In addition, the term "one or more salts" can include zwitterions (inner salts), for example, when the compound of formula (I) contains both a basic part (such as an amine or pyridine or imidazole ring) and an acidic part (such as a carboxylic acid). Pharmaceutically acceptable (i.e., nontoxic, physiologically acceptable) salts are preferred, such as acceptable metal salts and amine salts in which the cation does not contribute significantly to the toxicity or biological activity of the salt. However, other salts can be used, for example, in separation or purification steps that can be used during preparation, and are therefore covered within the scope of the present invention. The salt of the compound of formula (I) can be formed, for example, by reacting the compound of formula (I) with an amount (such as an equivalent amount) of acid or base in a medium (such as a medium in which the salt is precipitated) or in an aqueous medium, followed by freeze drying.

[0112] Exemplary acid addition salts include acetates (such as those formed with acetic acid or trihaloacetic acids (e.g., trifluoroacetic acid)), adipates, alginate, ascorbate, aspartate, benzoate, benzenesulfonate, bisulfate, borate, butyrate, citrate, camphorate, camphorsulfonate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, fumarate, glucoheptonate, glycerophosphate, hemisulfate, heptanoate, hexanoate, hydrochloride (formed with hydrochloric acid), hydrobromide (formed with hydrogen bromide), hydroiodide, maleate (formed with

[0013] The invention also includes but is not limited to bis(hydroxy)amino acids, ...

[0113] Exemplary basic salts include ammonium salts, alkali metal salts, such as sodium, lithium and potassium salts; alkaline earth metal salts, such as calcium and magnesium salts; barium, zinc and aluminum salts; salts formed with organic bases (e.g., organic amines), for example, trialkylamines (such as triethylamine), procaine, dibenzylamine, N-benzyl-β-phenethylamine, 1-aniline, N,N'-dibenzylethylene-diamine, dehydroabietinamine, N-ethylpiperidine, benzylamine, dicyclohexylamine or similar pharmaceutically acceptable amines, and salts formed with amino acids, such as arginine, lysine, and the like. Basic nitrogen-containing groups can be quaternized with agents such as lower alkyl halides (e.g., chlorides, bromides and iodides of methyl, ethyl, propyl and butyl), dialkyl sulfates (e.g., sulfates of dimethyl, diethyl, dibutyl and diamyl), long chain halides (e.g., chlorides, bromides and iodides of decyl, lauryl, myristyl and stearyl), aralkyl halides (e.g., bromides of benzyl and phenethyl), and other agents. Preferred salts include monohydrochlorides, bisulfates, methanesulfonates, phosphates or nitrates.

[0114] The compound of formula (I) may be provided as an amorphous solid or a crystalline solid. Lyophilization may be used to provide the compound of formula (I) as a solid.

[0115] It should also be understood that solvates (e.g., hydrates) of compounds of formula (I) are also within the scope of the present invention. The term "solvate" means a physical association of a compound of formula (I) with one or more solvent molecules (whether organic or inorganic). Such physical associations contain hydrogen bonds. In some cases, for example, when one or more solvent molecules are introduced into the lattice of a crystalline solid, the solvate will be able to separate. "Solvate" encompasses solution phase and separable solvates. Exemplary solvates include hydrates, ethanolates, methanolates, isopropanolates, acetonitrile solvates, and ethyl acetate solvates. Solvation methods are known in the art.

[0116] Various forms of prodrugs are known in the art and are described in Rautio, J. et al., Nature Review Drug Discovery, 17, 559-587 (2018).

[0117] In addition, the compound of formula (I) can be isolated and purified after its preparation to obtain a composition containing an amount of the compound of formula (I) equal to or greater than 99% by weight ("substantially pure"), and then used or formulated as described herein. Such "substantially pure" compounds of formula (I) are also considered to be part of the present invention herein.

[0118] "Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.The present invention is intended to include stable compounds.

[0119] A "therapeutically effective amount" is intended to include an amount of a compound of the invention alone or in combination with a plurality of compounds as claimed or in combination with other active ingredients that are effective in acting as DGKα and / or DGKζ inhibitors, or in the treatment or prevention of viral infections and proliferative disorders such as cancer.

[0120] As used herein, "treating" or "treatment" encompasses the treatment of a disease state in a mammal, particularly a human, and includes: (a) preventing the disease state from occurring in a mammal, particularly when such mammal is susceptible to the disease state but has not yet been diagnosed as having the disease state; (b) inhibiting the disease state, i.e., arresting its development; and / or (c) relieving the disease state, i.e., causing regression of the disease state.

[0121] The compounds of the invention are intended to include all isotopes of atoms occurring in the compounds of the invention. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example and not limitation, isotopes of hydrogen include deuterium (D) and tritium (T). Isotopes of carbon include 13 C and 14 C. Isotopically-labeled compounds of the present invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.

[0122] The compound according to formula (I) and / or pharmaceutically acceptable salts thereof may be administered by any means suitable for the condition to be treated, which may depend on the need for site-specific treatment or the amount of compound of formula (I) to be delivered.

[0123] The present invention also includes a class of pharmaceutical compositions, which include compounds of formula (I) and / or pharmaceutically acceptable salts thereof; and one or more non-toxic pharmaceutically acceptable carriers and / or diluents and / or adjuvants (collectively referred to herein as "carrier" materials) and (if desired) other active ingredients. The compound of formula (I) can be administered by any suitable route, preferably in the form of a pharmaceutical composition suitable for such a route, and at a dose effective for the intended treatment. The compounds and compositions of the present invention can be administered, for example, orally, mucosally, or parentally (including intravascularly, intravenously, intraperitoneally, subcutaneously, intramuscularly, and intrasternally) in a dosage unit formulation containing conventional pharmaceutically acceptable carriers, adjuvants, and vehicles. For example, the drug carrier can contain a mixture of mannitol or lactose and microcrystalline cellulose. The mixture can contain additional components, such as lubricants (e.g., magnesium stearate) and disintegrants (such as crospovidone). The carrier mixture can be filled into a gelatin capsule or pressed into a tablet. For example, the pharmaceutical composition can be administered as an oral dosage form or an infusion.

[0124] For oral administration, the pharmaceutical composition can be in the form of, for example, tablets, capsules, liquid capsules, suspensions or liquids. The pharmaceutical composition is preferably manufactured in the form of a dosage unit containing a specific amount of active ingredient. For example, the pharmaceutical composition can be provided in tablets or capsules, and the tablets or capsules are included in the active ingredient of the amount in the range of from about 0.1 to 1000 mg, preferably from about 0.25 to 250 mg, more preferably from about 0.5 to 100 mg. Depending on the patient's condition and other factors, the suitable daily dose for people or other mammals may vary greatly, but can be determined using conventional methods.

[0125] Any pharmaceutical composition considered herein can be, for example, delivered orally via any acceptable and suitable oral formulation. Exemplary oral formulations include, but are not limited to, for example, tablets, lozenges, lozenges, aqueous and oily suspensions, dispersible powders or granules, emulsions, hard and soft capsules, liquid capsules, syrups and elixirs. The pharmaceutical composition intended for oral administration can be prepared according to any method known in the art for making the pharmaceutical composition intended for oral administration. In order to provide pharmaceutically palatable preparations, the pharmaceutical composition according to the present invention can contain at least one agent selected from sweeteners, flavoring agents, coloring agents, demulcents, antioxidants and preservatives.

[0126] Tablets can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one non-toxic pharmaceutically acceptable excipient suitable for making tablets. Exemplary excipients include, but are not limited to, for example, inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate and sodium phosphate; granulating agents and disintegrants such as microcrystalline cellulose, cross-linked sodium carboxymethyl cellulose, corn starch and alginic acid; binders such as starch, gelatin, polyvinyl pyrrolidone and gum arabic; and lubricants such as magnesium stearate, stearic acid and talc. In addition, tablets can be uncoated or coated by known techniques to mask the unpleasant taste of drugs that taste unpleasant, or to delay the disintegration and absorption of active ingredients in the gastrointestinal tract, thereby maintaining the action of the active ingredient for a longer period of time. Exemplary water-soluble taste masking materials include, but are not limited to, hydroxypropyl methylcellulose and hydroxypropyl cellulose. Exemplary time-delay materials include, but are not limited to, ethyl cellulose and cellulose acetate butyrate.

[0127] Hard gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one salt thereof with at least one inert solid diluent such as, for example, calcium carbonate, calcium phosphate and kaolin.

[0128] Soft gelatin capsules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one water-soluble carrier (such as, for example, polyethylene glycol) and at least one oil medium (such as, for example, peanut oil, liquid paraffin and olive oil).

[0129] Aqueous suspensions can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one excipient suitable for producing an aqueous suspension. Exemplary excipients suitable for making aqueous suspensions include, but are not limited to, for example, suspending agents, such as, for example, sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, alginic acid, polyvinyl pyrrolidone, tragacanth and gum arabic; dispersants or wetting agents, such as, for example, naturally occurring phospholipids, such as lecithin; condensation products of alkylene oxides with fatty acids, such as, for example, polyoxyethylene stearate; condensation products of ethylene oxide with long-chain aliphatic alcohols, such as, for example, heptadecanedeylene-oxycetanol; condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol, such as, for example, polyoxyethylene sorbitol monooleate; and condensation products of ethylene oxide with partial esters derived from fatty acids and hexitol anhydrides, such as, for example, polyethylene sorbitan monooleate. The aqueous suspension may also contain at least one preservative, such as, for example, ethyl and n-propyl p-hydroxybenzoate; at least one coloring agent; at least one flavoring agent; and / or at least one sweetening agent, including, but not limited to, for example, sucrose, saccharin, and aspartame.

[0130] Oily suspensions can be prepared, for example, by suspending at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof in a vegetable oil (e.g., such as peanut oil, olive oil, sesame oil and coconut oil) or in a mineral oil (e.g., such as liquid paraffin). Oily suspensions can also contain at least one thickening agent, such as, for example, beeswax, hard paraffin and hexadecanol. In order to provide a palatable oily suspension, at least one sweetener and / or at least one flavoring agent described above can be added to the oily suspension. Oily suspensions can further contain at least one preservative, including but not limited to, for example, antioxidants, such as, for example, butylated hydroxyanisole and alpha-tocopherol.

[0131] Dispersible powders and granules can be prepared, for example, by mixing at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof with at least one dispersant and / or wetting agent, at least one suspending agent and / or at least one preservative. Suitable dispersants, wetting agents and suspending agents are as described above. Exemplary preservatives include, but are not limited to, for example, antioxidants, such as ascorbic acid. In addition, dispersible powders and granules can also contain at least one excipient, including, but not limited to, for example, sweeteners, flavoring agents and coloring agents.

[0132] The emulsion of at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof can be prepared, for example, as an oil-in-water emulsion. The oil phase of the emulsion comprising the compound of formula (I) can be composed of known ingredients in a known manner. The oil phase can be provided by, for example, but not limited to, vegetable oils (e.g., such as olive oil and peanut oil), mineral oils (e.g., such as liquid paraffin) and mixtures thereof. Although the phase can contain only an emulsifier, it can contain at least one emulsifier and a fat or oil or a mixture of both a fat and an oil. Suitable emulsifiers include, for example, but are not limited to, natural phospholipids, such as soybean lecithin; esters or partial esters derived from fatty acids and hexitol anhydrides, such as sorbitan monooleate; and condensation products of partial esters with ethylene oxide, such as polyoxyethylene sorbitan monooleate. Preferably, a hydrophilic emulsifier is included together with a lipophilic emulsifier, which acts as a stabilizer. It is also preferred to include both oil and fat. One or more emulsifiers together with or without one or more stabilizers constitute the so-called emulsifying wax, and wax together with oil and fat constitute the so-called emulsifying ointment base, which forms the oily dispersed phase of the cream formulation. The emulsion can also contain sweeteners, flavorings, preservatives and / or antioxidants. Emulsifiers and emulsion stabilizers suitable for the formulation of the present invention include Tween 60, Span 80, cetearyl alcohol, myristyl alcohol, glyceryl monostearate, sodium lauryl sulfate, distearic acid glyceryl alone or with wax, or other materials well known in the art.

[0133] The compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof can also be delivered, for example, intravenously, subcutaneously and / or intramuscularly by any pharmaceutically acceptable and suitable injectable form. Exemplary injectable forms include, but are not limited to, for example, sterile aqueous solutions containing acceptable vehicles and solvents, such as water, Ringer's solution, and isotonic sodium chloride solution; sterile oil-in-water microemulsions; and aqueous or oily suspensions.

[0134] Preparations for parenteral administration can be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions can be prepared by sterile powders or granules using one or more carriers or diluents mentioned for use in preparations for oral administration or by using other suitable dispersants or wetting agents and suspending agents. The compound can be dissolved in water, polyethylene glycol, propylene glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, tragacanth and / or various buffers. Other adjuvants and modes of administration are well known and well known in the pharmaceutical field. The active ingredient can also be administered by injection as a composition with a suitable carrier (including saline, dextrose or water) or with cyclodextrin (i.e. Captisol), co-solvent solubilization (i.e. propylene glycol) or micellar solubilization (i.e. Tween 80).

[0135] Sterile injectable preparations can also be sterile injectable solutions or suspensions in nontoxic parenteral acceptable diluents or solvents, for example as solutions in 1,3-butanediol. The acceptable usable vehicles and solvents are water, Ringer's solution and isotonic sodium chloride solution. In addition, conventionally sterile fixed oils are used as solvents or suspension media. For this purpose, any gentle non-volatile oils can be used, including synthetic monoglycerides or diglycerides. In addition, fatty acids (such as oleic acid) can be used to prepare injections.

[0136] Sterile injectable oil-in-water microemulsions can be prepared, for example, by 1) dissolving at least one compound of formula (I) in an oil phase (such as, for example, a mixture of soybean oil and lecithin); 2) combining the oil phase containing formula (I) with a mixture of water and glycerol; and 3) processing the combination to form a microemulsion.

[0137] Sterile aqueous or oily suspensions can be prepared according to methods known in the art. For example, sterile aqueous solutions or suspensions can be prepared with nontoxic parenterally acceptable diluents or solvents (such as, for example, 1,3-butanediol); and sterile oily suspensions can be prepared with sterile nontoxic acceptable solvents or suspending media (such as, for example, sterile nonvolatile oils, such as synthetic monoglycerides or diglycerides; and fatty acids, such as, for example, oleic acid).

[0138] Pharmaceutically acceptable carriers, adjuvants and vehicles that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopheryl polyethylene glycol 1000 succinate, surfactants for pharmaceutical dosage forms such as Tweens, polyethoxylated castor oils such as CREMOPHOR surfactant (BASF), or other similar polymer delivery matrices, serum proteins such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts), colloidal silicon dioxide, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block polymers, polyethylene glycol and lanolin. Cyclodextrins such as α-, β- and γ-cyclodextrin or chemically modified derivatives such as hydroxyalkylcyclodextrins (including 2- and 3-hydroxypropyl-cyclodextrin) or other solubilized derivatives may also be advantageously used to enhance delivery of compounds of the formulae described herein.

[0139] The pharmaceutically active compounds of the present invention can be processed according to conventional pharmaceutical methods to produce medical medicaments for administration to patients (including humans and other mammals). The pharmaceutical compositions can be subjected to conventional pharmaceutical operations such as sterilization and / or can contain conventional adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, buffers, etc. Such compositions may also include adjuvants such as wetting agents, sweeteners, flavoring agents and aromatics.

[0140] The amount of the compound applied and the dosage regimen for treating the condition with the compound and / or composition of the present invention depend on various factors, including the age, weight, sex, medical condition, disease type, severity of the disease, route of administration and frequency, and the specific compound used of the subject. Therefore, the dosage regimen can be widely varied, but can be routinely determined using standard methods. The daily dosage of about 0.001 to 100 mg / kg body weight, preferably between about 0.0025 and about 50 mg / kg body weight and most preferably between about 0.005 to 10 mg / kg body weight may be appropriate. The daily dosage can be applied by 1 to 4 times / day. Other dosage regimens include one dose / week and one dose / two-day cycle.

[0141] For therapeutic purposes, the active compound of the present invention is usually combined with one or more adjuvants suitable for the indicated route of administration. If administered orally, the compound can be mixed with lactose, sucrose, starch powder, cellulose esters of alkanoic acid, cellulose alkyl esters, talcum powder, stearic acid, magnesium stearate, magnesium oxide, sodium salts and calcium salts of phosphoric acid and sulfuric acid, gelatin, gum arabic, sodium alginate, polyvinyl pyrrolidone and / or polyvinyl alcohol, and then tableting or encapsulation are used conveniently. Such capsules or tablets can contain controlled release formulations, which can be provided in the dispersion of the active compound in hydroxypropyl methylcellulose.

[0142] The pharmaceutical composition of the present invention comprises at least one compound of formula (I) and / or at least one pharmaceutically acceptable salt thereof and an additional agent optionally selected from any pharmaceutically acceptable carrier, adjuvant and vehicle. An alternative composition of the present invention comprises a compound of formula (I) as described herein or a prodrug thereof and a pharmaceutically acceptable carrier, adjuvant or vehicle.

[0143] utility

[0144] The compounds of formula (I) are useful for treating cancer.

[0145] In another embodiment, the present invention provides a combined preparation of a compound of formula (I) and / or a pharmaceutically acceptable salt thereof, a stereoisomer or a tautomer thereof, and one or more additional therapeutic agents for simultaneous, separate or sequential use in the treatment and / or prevention of a variety of diseases or disorders associated with DGK target inhibition in T cells.

[0146] In another aspect, the present invention provides a method for treating a patient suffering from or susceptible to a medical condition associated with DGK target inhibition in T cells. A variety of medical conditions can be treated. The method comprises administering to the patient a therapeutically effective amount of a composition comprising a compound of formula (I) and / or a pharmaceutically acceptable salt thereof, a stereoisomer thereof, or a tautomer thereof. For example, the compounds described herein can be used to treat or prevent viral infections and proliferative diseases, such as cancer.

[0147] Compounds of formula (I) and pharmaceutical compositions comprising at least one compound of formula (I) can be used to treat or prevent any disease or condition associated with DGK target inhibition in T cells. They include viral infections and other infections (e.g., skin infections, GI infections, urinary tract infections, genitourinary infections, systemic infections) and proliferative diseases (e.g., cancer). Compounds of formula (I) and pharmaceutical compositions comprising at least one compound of formula (I) can be applied to animals, preferably mammals (e.g., domestic animals, cats, dogs, mice, rats), and more preferably humans. Any method of administration can be used to deliver the compound or pharmaceutical composition to the patient. In certain embodiments, a compound of formula (I) or a pharmaceutical composition comprising at least a compound of formula (I) is orally administered. In other embodiments, a pharmaceutical composition comprising at least a compound of formula (I) or a compound of formula (I) is administered parenterally.

[0148] The compounds of formula (I) can inhibit the activity of diacylglycerol kinase α and ζ (DGKα / ζ). For example, the compounds of formula (I) can be used to inhibit the activity of DGKα and DGKζ in cells or in individuals who need to regulate DGKα and DGKζ by administering an inhibitory amount of the compound of formula (I) or a salt thereof.

[0149] The present invention further provides a method for treating a disease associated with the activity or expression (including abnormal activity and / or overexpression) of DGKα and DGKζ in an individual (e.g., a patient) by administering a therapeutically effective amount or dose of a compound of formula (I) or a pharmaceutical composition thereof to an individual in need of such treatment. Examples of diseases may include any disease, disorder, or condition directly or indirectly associated with the expression or activity of DGKα and DGKζ enzymes (such as overexpression or abnormal activity). DGKα and DGKζ related diseases may also include any disease, disorder, or condition that can be prevented, improved, or cured by regulating the activity of DGKα and DGKζ enzymes. Examples of DGKα and DGKζ related diseases include cancer and viral infections, such as HIV infection, hepatitis B, and hepatitis C.

[0150] In one aspect, one or more compounds of formula (I) are administered sequentially prior to administration of an immuno-oncology agent. In another aspect, one or more compounds of formula (I) are administered simultaneously with an immuno-oncology agent. In yet another aspect, one or more compounds of formula (I) are administered sequentially after administration of an immuno-oncology agent.

[0151] In another aspect, the compounds of formula (I) may be co-formulated with an immuno-oncology agent.

[0152] Immuno-oncology agents include, for example, small molecule drugs, antibodies, or other biological or small molecules. Examples of biological immuno-oncology agents include, but are not limited to, cancer vaccines, antibodies, and cytokines. In one aspect, the antibody is a monoclonal antibody. In another aspect, the monoclonal antibody is humanized or human.

[0153] In one aspect, the immuno-oncology agent is either (i) an agonist of a stimulatory (including co-stimulatory) receptor, or (ii) an antagonist of an inhibitory (including co-inhibitory) signal on T cells, both of which result in the amplification of antigen-specific T cell responses (often referred to as immune checkpoint modulators).

[0154] Some stimulatory and inhibitory molecules are members of the immunoglobulin superfamily (IgSF). An important family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the B7 family, which includes B7-1, B7-2, B7-H1 (PD-L1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6. Another family of membrane-bound ligands that bind to co-stimulatory or co-inhibitory receptors is the TNF family of molecules that bind to homologous TNF receptor family members, including CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137 (4-1BB), TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, RAN KL, TWEAKR / Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LTβR, LIGHT, DcR3, HVEM, VEGI / TL1A, TRAMP / DR 3. EDAR, EDA1, XEDAR, EDA2, TNFR1, lymphotoxin α / TNFβ, TNFR2, TNFα, LTβR, lymphotoxin α1β2, FAS, FASL, RELT, DR6, TROY, NGFR.

[0155] In one aspect, T cell responses can be stimulated by a combination of a compound of formula (I) and one or more of the following: (i) antagonists (e.g., immune checkpoint inhibitors) of proteins that inhibit T cell activation (such as CTLA-4, PD-1, PD-L1, PD-L2, LAG-3, TIM-3, galectin 9, CEACAM-1, BTLA, CD69, galectin-1, TIGIT, CD113, GPR56, VISTA, 2B4, CD48, GARP, PD1H, LAIR1, TIM-1, and TIM-4), and (ii) agonists of proteins that stimulate T cell activation (such as B7-1, B7-2, CD28, 4-1BB (CD137), 4-1BBL, ICOS, ICOS-L, OX40, OX40L, GITR, GITRL, CD70, CD27, CD40, DR3, and CD28H).

[0156] Other agents that can be combined with compounds of formula (I) for the treatment of cancer include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells. For example, compounds of formula (I) can be combined with antagonists of KIR (such as lirilumab).

[0157] Still other agents for combination therapy include agents that inhibit or deplete macrophages or monocytes, including but not limited to CSF-1R antagonists, such as CSF-1R antagonist antibodies, including RG7155 (WO11 / 70024, WO11 / 107553, WO11 / 131407, WO13 / 87699, WO13 / 119716, WO13 / 132044) or FPA-008 (WO11 / 140249; WO13169264; WO14 / 036357).

[0158] In another aspect, the compounds of formula (I) can be used with one or more of the following: agonists that bind positive co-stimulatory receptors, blockers that attenuate signaling through inhibitory receptors, antagonists, and one or more agents that systemically increase the frequency of anti-tumor T cells, overcome different immunosuppressive pathways in the tumor microenvironment (e.g., blocking inhibitory receptor engagement (e.g., PD-L1 / PD-1 interaction), deplete or inhibit Tregs (e.g., using anti-CD25 monoclonal antibodies (e.g., daclizumab) or by ex vivo anti-CD25 bead depletion), inhibit metabolic enzymes (such as IDO), or reverse / prevent T cell anergy or exhaustion) and agents that trigger innate immune activation and / or inflammation at the tumor site.

[0159] In one aspect, the immuno-oncology agent is a CTLA-4 antagonist, such as an antagonist CTLA-4 antibody. Suitable CTLA-4 antibodies include, for example, YERVOY (ipilimumab) or tremelimumab.

[0160] In another aspect, the immuno-oncology agent is a PD-1 antagonist, such as an antagonist PD-1 antibody. Suitable PD-1 antibodies include, for example, OPDIVO (nivolumab), KEYTRUDA (pembrolizumab), or MEDI-0680 (AMP-514; WO2012 / 145493). Immuno-oncology agents may also include pidilizumab (CT-011), although its specificity for PD-1 binding is questionable. Another approach to targeting the PD-1 receptor is a recombinant protein consisting of the extracellular domain of PD-L2 (B7-DC) fused to the Fc portion of IgG1, called AMP-224.

[0161] In another aspect, the immuno-oncology agent is a PD-L1 antagonist, such as an antagonist PD-L1 antibody. Suitable PD-L1 antibodies include, for example, MPDL3280A (RG7446; WO2010 / 077634), durvalumab (MEDI4736), BMS-936559 (WO2007 / 005874), and MSB0010718C (WO2013 / 79174).

[0162] In another aspect, the immuno-oncology agent is a LAG-3 antagonist, such as an antagonist LAG-3 antibody. Suitable LAG3 antibodies include, for example, BMS-986016 (WO10 / 19570, WO14 / 08218), or IMP-731 or IMP-321 (WO08 / 132601, WO09 / 44273).

[0163] In another aspect, the immuno-oncology agent is a CD137 (4-1BB) agonist, such as an agonistic CD137 antibody. Suitable CD137 antibodies include, for example, urelumab and PF-05082566 (WO12 / 32433).

[0164] In another aspect, the immuno-oncology agent is a GITR agonist, such as an agonistic GITR antibody. Suitable GITR antibodies include, for example, BMS-986153, BMS-986156, TRX-518 (WO06 / 105021, WO09 / 009116), and MK-4166 (WO11 / 028683).

[0165] In another aspect, the immuno-oncology agent is an IDO antagonist. Suitable IDO antagonists include, for example, INCB-024360 (WO2006 / 122150, WO07 / 75598, WO08 / 36653, WO08 / 36642), indoximod, BMS-986205, or NLG-919 (WO09 / 73620, WO09 / 1156652, WO11 / 56652, WO12 / 142237).

[0166] In another aspect, the immuno-oncology agent is an OX40 agonist, such as an agonistic OX40 antibody. Suitable OX40 antibodies include, for example, MEDI-6383 or MEDI-6469.

[0167] In another aspect, the immuno-oncology agent is an OX40L antagonist, such as an antagonist OX40 antibody. Suitable OX40L antagonists include, for example, RG-7888 (WO06 / 029879).

[0168] In another aspect, the immuno-oncology agent is a CD40 agonist, such as an agonistic CD40 antibody. In yet another embodiment, the immuno-oncology agent is a CD40 antagonist, such as an antagonist CD40 antibody. Suitable CD40 antibodies include, for example, lucatumumab or dacetuzumab.

[0169] In another aspect, the immuno-oncology agent is a CD27 agonist, such as an agonistic CD27 antibody. Suitable CD27 antibodies include, for example, varlilumab.

[0170] In another aspect, the immuno-oncology agent is MGA271 (directed against B7H3) (WO 11 / 109400).

[0171] Combination therapy is intended to include the administration of these therapeutic agents in a sequential manner (i.e., wherein each therapeutic agent is administered at different times) and the administration of these therapeutic agents or at least two of these therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dosage form of each therapeutic agent with a fixed ratio or with multiple single dosage forms of each therapeutic agent. Sequential or substantially simultaneous administration of each therapeutic agent can be achieved by any appropriate route, including but not limited to oral routes, intravenous routes, intramuscular routes, and direct absorption by mucosal tissue. The therapeutic agent can be administered by the same route or by different routes. For example, the first therapeutic agent in the combination can be administered by intravenous injection, while the other therapeutic agents in the combination can be administered orally. Alternatively, for example, the therapeutic agent can be administered orally or all therapeutic agents can be administered by intravenous injection. Combination therapy can also include the further administration of the therapeutic agent as described above in combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiotherapy). In the case where combination therapy further includes non-drug therapy, the non-drug therapy can be performed at any appropriate time, as long as the beneficial effect is achieved from the combined action of the therapeutic agent and the combination of non-drug therapy. For example, in appropriate circumstances, when the non-drug therapy is temporarily removed from the administration of the therapeutic agent (perhaps for days or even weeks), the beneficial effects are still achieved.

[0172] As used herein, the term "cell" is intended to refer to a cell in vitro, ex vivo, or in vivo. In some embodiments, an ex vivo cell can be a part of a tissue sample excised from an organism (such as a mammal). In some embodiments, an in vitro cell can be a cell in a cell culture. In some embodiments, an in vivo cell is a cell living in an organism (such as a mammal).

[0173] As used herein, the term "contacting" refers to bringing the indicated parts together in an in vitro system or an in vivo system. For example, "contacting" the DGKα and DGKζ enzymes with a compound of formula (I) includes administering a compound of the invention to an individual or patient (such as a human) having DGKα and DGKζ, and, for example, introducing a compound of formula (I) into a sample containing cells or purified preparations containing DGKα and DGKζ enzymes.

[0174] The term "DGKα and DGKζ inhibitor" refers to an agent that is capable of inhibiting the activity of diacylglycerol kinase α and / or diacylglycerol kinase ζ (DGKα and DGKζ) in T cells, thereby resulting in T cell stimulation. DGKα and DGKζ inhibitors can be reversible or irreversible DGKα and DGKζ inhibitors. "Reversible DGKα and DGKζ inhibitors" are compounds that reversibly inhibit the enzymatic activity of DGKα and DGKζ at the catalytic site or the non-catalytic site, and "irreversible DGKα and DGKζ inhibitors" are compounds that irreversibly destroy the enzymatic activity of DGKα and DGKζ by forming a covalent bond with the enzyme.

[0175] The types of cancers that can be treated with compounds of formula (I) include, but are not limited to, brain cancer, skin cancer, bladder cancer, ovarian cancer, breast cancer, stomach cancer, pancreatic cancer, prostate cancer, colon cancer, blood cancer, lung cancer, and bone cancer. Examples of such cancer types include neuroblastoma, intestinal cancer (such as rectal cancer, colon cancer, familiar adenomatous polyposis and hereditary non-polyposis colorectal cancer), esophageal cancer, lip cancer, laryngeal cancer, hypopharyngeal cancer, tongue cancer, salivary gland cancer, stomach cancer, adenocarcinoma, medullary thyroid cancer, papillary thyroid cancer, kidney cancer, renal parenchymal cancer, ovarian cancer, cervical cancer, uterine corpus cancer, endometrial cancer, choriocarcinoma, pancreatic cancer, prostate cancer, testicular cancer, breast cancer, urinary tract cancer, melanoma, brain tumors (such as glioblastoma, astrocytoma, meningioma, medulloblastoma, and peripheral neuroectodermal tumor), Hodgkin's lymphoma, Non-Hodgkin lymphoma, Burkeley lymphoma, acute lymphoid leukemia (ALL), chronic lymphoid leukemia (CLL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), adult T-cell leukemia lymphoma, diffuse large B-cell lymphoma (DLBCL), hepatocellular carcinoma, gallbladder cancer, bronchial carcinoma, small cell lung cancer, non-small cell lung cancer, multiple myeloma, basal cell carcinoma, teratoma, retinoblastoma, choroidal melanoma, seminoma, rhabdomyosarcoma, craniopharyngioma, osteosarcoma, chondrosarcoma, myosarcoma, liposarcoma, fibrosarcoma, Ewing sarcoma and plasmacytoma.

[0176] One or more additional agents or treatments (e.g., such as antiviral agents, chemotherapeutic agents or other anticancer agents, immunopotentiators, immunosuppressants, radiation, anti-tumor and antiviral vaccines, cytokine therapy (e.g., IL2 and GM-CSF), and / or tyrosine kinase inhibitors) may optionally be combined with compounds of formula (I) for the treatment of DGKα and DGKζ-related diseases, disorders or conditions. The agents may be combined with the compounds of the invention in a single dosage form, or the agents may be administered simultaneously or sequentially as separate dosage forms.

[0177] Suitable chemotherapeutic or other anticancer agents include, for example, alkylating agents (including but not limited to nitrogen mustards, ethyleneimine derivatives, alkyl sulfonates, nitrosoureas, and triazenes), such as uracil mustard, chlormethine, cyclophosphamide, Ifosfamide, melphalan, chlorambucil, pipobroman, triethylene-melamine, triethylenethiophosphoramide, busulfan, carmustine, lomustine, streptozotocin, dacarbazine, and temozolomide.

[0178] In the treatment of melanoma, suitable agents for use in combination with compounds of formula (I) include: dacarbazine (DTIC), optionally together with other chemotherapy drugs such as carmustine (BCNU) and cisplatin; the "Dartmouth regimen", which consists of DTIC, BCNU, cisplatin and tamoxifen; cisplatin, vinblastine and DTIC, temozolomide or YERVOY TM In the treatment of melanoma, the compounds of formula (I) may also be combined with immunotherapy drugs, including cytokines, such as interferon alpha, interleukin 2 and tumor necrosis factor (TNF).

[0179] Compounds of formula (I) may also be used in combination with vaccine therapy to treat melanoma. Anti-melanoma vaccines are similar in some respects to antiviral vaccines used to prevent diseases caused by viruses (polio, measles and mumps). Weakened melanoma cells or parts of melanoma cells (called antigens) may be injected into a patient to stimulate the body's immune system to destroy melanoma cells.

[0180] Melanoma confined to the arms or legs can also be treated with a combination of agents including one or more compounds of formula (I) using a hyperthermic isolated limb perfusion technique. This treatment regimen temporarily separates the circulation of the affected limb from the rest of the body, and high doses of chemotherapy are injected into the arteries that supply blood to the limb, thereby providing high doses to the tumor area without exposing the internal organs to these doses that otherwise cause serious side effects. Typically, the fluid is warmed to 38.9°C to 40°C. Melphalan is the most commonly used drug in this chemotherapy. This can be given together with another agent called tumor necrosis factor (TNF).

[0181] Suitable chemotherapeutic or other anticancer agents include, for example, antimetabolites (including but not limited to folate antagonists, pyrimidine analogs, purine analogs, and adenosine deaminase inhibitors) such as methotrexate, 5-fluorouracil, floxuridine, cytarabine, 6-mercaptopurine, 6-thioguanine, fludarabine phosphate, pentostatine, and gemcitabine.

[0182] Suitable chemotherapeutic or other anticancer agents further include, for example, certain natural products and their derivatives (e.g., vinca alkaloids, antitumor antibiotics, enzymes, lymphokines and epipodophyllotoxins), such as vinblastine, vincristine, vindesine, bleomycin, dactinomycin, daunorubicin, doxorubicin, epirubicin, idarubicin, ara-C, paclitaxel (Taxol), mithramycin, deoxycoformycin, mitomycin-C, L-asparaginase, interferons (particularly IFN-a), etoposide and teniposide.

[0183] Other cytotoxic agents include navelbene, CPT-11, anastrazole, letrozole, capecitabine, and droloxafine.

[0184] Also suitable are cytotoxic agents such as epidophyllotoxin; antitumor enzymes; topoisomerase inhibitors; procarbazine; mitoxantrone; platinum coordination complexes such as cisplatin and carboplatin; biological response modifiers; growth inhibitory agents; antihormonal therapeutics; folinic acid; tegafur; and hematopoietic growth factors.

[0185] One or more other anti-cancer agents including antibody therapeutics such as trastuzumab Antibodies against co-stimulatory molecules (such as CTLA-4, 4-1BB and PD-1), or antibodies against cytokines (IL-10 or TGF-β).

[0186] Other anticancer agents also include those that block the migration of immune cells, such as antagonists of chemokine receptors, including CCR2 and CCR4.

[0187] Other anti-cancer agents also include those that enhance the immune system such as helper or adoptive T cell transfer.

[0188] Anticancer vaccines include dendritic cells, synthetic peptides, DNA vaccines, and recombinant viruses.

[0189] The pharmaceutical composition of the present invention may optionally contain at least one signal transduction inhibitor (STI). A "signal transduction inhibitor" is an agent that selectively inhibits one or more important steps in the signal transduction pathway (in the normal function of cancer cells), thereby leading to apoptosis. Suitable STIs include, but are not limited to: (i) bcr / abl kinase inhibitors, such as STI 571 (ii) epidermal growth factor (EGF) receptor inhibitors, such as kinase inhibitors ( SSI-774) and antibodies (Imclone: ​​C225 [Goldstein et al., Clin. Cancer Res., 1: 1311-1318 (1995)] and Abgenix: ABX-EGF); (iii) her-2 / neu receptor inhibitors, such as farnesyl transferase inhibitors (FTIs), such as, for example, L-744,832 (Kohl et al., Nat. Med., 1(8): 792-797 (1995)); (iv) inhibitors of Akt family kinases or Akt pathways, such as, for example, rapamycin (see, e.g., Sekulic et al., Cancer Res., 1(8): 792-797 (1995)); Res., 60:3504-3513 (2000)); (v) cell cycle kinase inhibitors, such as, for example, flavonoids and UCN-O1 (see, for example, Sausville, Curr. Med. Chem. Anti-Canc. Agents, 3:47-56 (2003)); and (vi) phosphatidylinositol kinase inhibitors, such as, for example, LY294002 (see, for example, Vlahos et al., J. Biol. Chem., 269:5241-5248 (1994)). Alternatively, at least one STI and at least one compound of formula (I) may be in separate pharmaceutical compositions. In a specific embodiment of the present invention, at least one compound of formula (I) and at least one STI may be administered to a patient simultaneously or sequentially. In other words, at least one compound of formula (I) may be administered first, at least one STI may be administered first, or at least one compound of formula (I) and at least one STI may be administered simultaneously. Additionally, when more than one compound of formula (I) and / or STI is used, the compounds may be administered in any order.

[0190] The present invention further provides a pharmaceutical composition for treating a chronic viral infection in a patient, comprising at least one compound of formula (I), optionally at least one chemotherapeutic agent, and optionally at least one antiviral agent in a pharmaceutically acceptable carrier.

[0191] Also provided is a method for treating chronic viral infection in a patient by administering an effective amount of the above pharmaceutical composition.

[0192] In a specific embodiment of the invention, at least one compound of formula (I) and at least one chemotherapeutic agent may be administered to a patient simultaneously or sequentially. In other words, at least one compound of formula (I) may be administered first, at least one chemotherapeutic agent may be administered first, or at least one compound of formula (I) and at least one STI may be administered simultaneously. In addition, when more than one compound of formula (I) and / or chemotherapeutic agent is used, the compounds may be administered in any order. Similarly, any antiviral agent or STI may also be administered at any point compared to the administration of the compound of formula (I).

[0193] Chronic viral infections that can be treated using the combination therapy of the present invention include, but are not limited to, diseases caused by: Hepatitis C virus (HCV), human papillomavirus (HPV), cytomegalovirus (CMV), herpes simplex virus (HSV), Epstein-Barr virus (EBV), varicella zoster virus, coxsackie virus, human immunodeficiency virus (HIV). Notably, parasitic infections (e.g., malaria) can also be treated by the above method, wherein compounds known to treat parasitic disorders are optionally added in place of antiviral agents.

[0194] Suitable antiviral agents contemplated for use in combination with the compounds of formula (I) may include nucleoside and nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors and other antiviral drugs.

[0195] Exemplary suitable NRTIs include zidovudine (AZT); didanosine (ddl); zalcitabine (ddC); stavudine (d4T); lamivudine (3TC); abacavir (1592U89); adefovir dipivoxil [bis(POM)-PMEA]; lobucavir; BCH-I0652; emtricitabine [(-)-FTC]; β-L-FD4 (also known as β-L-D4C and designated β-L-2',3'-dideoxy-5-fluoro-cytidine (cytidene)); DAPD ((-)-β-D-2,6-diamino-purine dioxolane); and lodenosine (FddA). Typical suitable NNRTIs include nevirapine (BI-RG-587); delaviradine (BHAP, U-90152); efavirenz (DMP-266); PNU-142721; AG-1549; MKC-442 (1-(ethoxy-methyl)-5-(1-methylethyl)-6-(phenylmethyl)-(2,4(1H,3H)-pyrimidinedione); and (+)-tonolide A (NSC-675451) and B. Typical suitable protease inhibitors The agents include saquinavir (Ro31-8959); ritonavir (ABT-538); indinavir (MK-639); nelfinavir (AG-1343); amprenavir (141W94); lasinavir; DMP-450; BMS-2322623; ABT-378; and AG-1549. Other antiviral agents include hydroxyurea, ribavirin, IL-2, IL-12, pentafuside, and Yissum Project No. 11607.

[0196] The present invention also includes a pharmaceutical kit that can be used, for example, to treat or prevent DGKα and DGKζ related diseases or disorders and other diseases mentioned herein, which includes one or more containers containing a pharmaceutical composition, the pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I). If desired, such a kit may further include one or more of the following: various conventional pharmaceutical kit components, such as containers with one or more pharmaceutically acceptable carriers, additional containers, which will be readily apparent to those skilled in the art. The kit may also include instructions as inserts or as labels, indicating the amount of the components to be administered, administration instructions, and / or instructions for mixing the components.

[0197] Combination therapy is intended to include the administration of these therapeutic agents in a sequential manner (i.e., wherein each therapeutic agent is administered at different times) and the administration of these therapeutic agents or at least two of these therapeutic agents in a substantially simultaneous manner. Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single dosage form of each therapeutic agent with a fixed ratio or with multiple single dosage forms of each therapeutic agent. Sequential or substantially simultaneous administration of each therapeutic agent can be achieved by any appropriate route, including but not limited to oral routes, intravenous routes, intramuscular routes, and direct absorption by mucosal tissue. The therapeutic agent can be administered by the same route or by different routes. For example, the first therapeutic agent in the combination can be administered by intravenous injection, while the other therapeutic agents in the combination can be administered orally. Alternatively, for example, the therapeutic agent can be administered orally or all therapeutic agents can be administered by intravenous injection. Combination therapy can also include the further administration of the therapeutic agent as described above in combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiotherapy). In the case where combination therapy further includes non-drug therapy, the non-drug therapy can be performed at any appropriate time, as long as the beneficial effect is achieved from the combined action of the therapeutic agent and the combination of non-drug therapy. For example, in appropriate circumstances, when the non-drug therapy is temporarily removed from the administration of the therapeutic agent (perhaps for days or even weeks), the beneficial effects are still achieved.

[0198] The present invention also provides pharmaceutically acceptable compositions comprising a therapeutically effective amount of one or more compounds of formula (I) formulated together with one or more pharmaceutically acceptable carriers (additives) and / or diluents, and optionally one or more additional therapeutic agents as described above.

[0199] The compounds of the invention may be administered for any of the uses described herein by any suitable means: for example, orally (such as tablets, capsules (each of which includes sustained release or timed release formulations), pills, powders, granules, elixirs, tinctures, suspensions (including nanosuspensions, microsuspensions, spray-dried dispersions), syrups and emulsions); sublingually; buccally; parenterally, such as by subcutaneous, intravenous, intramuscular or intrasternal injection or infusion techniques (e.g., as a sterile injectable aqueous or non-aqueous solution or suspension); intranasally, including application to the nasal membrane, such as by inhalation spray; topically, such as in the form of a cream or ointment; or rectally, such as in the form of a suppository. They can be administered alone, but will generally be administered with a pharmaceutical carrier selected based on the chosen route of administration and standard pharmaceutical practice.

[0200] As used herein, the phrase "pharmaceutically acceptable carrier" means a pharmaceutically acceptable material, composition or vehicle, such as a liquid or solid filler, diluent, excipient, manufacturing aid (e.g., lubricant, magnesium talc, calcium or zinc stearate, or stearic acid), or solvent encapsulating material, which participates in carrying or transporting the subject compound from one organ or part of the body to another organ or part of the body. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient, the other ingredients including: that is, adjuvants, excipients or vehicles such as diluents, preservatives, fillers, flow regulators, disintegrants, wetting agents, emulsifiers, suspending agents, sweeteners, flavoring agents, perfuming agents, antibacterial agents, antifungal agents, lubricants and dispensing agents, depending on the mode of administration and dosage form.

[0201] The term "pharmaceutical composition" means a composition comprising a compound of the present invention in combination with at least one additional pharmaceutically acceptable carrier.

[0202] Pharmaceutically acceptable carriers are formulated according to many factors within the scope of cognition of ordinary technicians in the field. They include, but are not limited to, the type and nature of the active agent to be formulated; the subject to be administered the composition containing the medicament; the expected route of administration of the composition; and the target therapeutic indication. Pharmaceutically acceptable carriers include both aqueous and non-aqueous liquid media, as well as various solid and semi-solid dosage forms. Such carriers may also include many different ingredients and additives in addition to the active agent, and such additional ingredients are included in the formulation for a variety of reasons well known to ordinary technicians in the field (e.g., stabilization of active agents, adhesives, etc.). Descriptions of suitable pharmaceutically acceptable carriers and factors involved in their selection are found in a variety of readily available sources, such as Allen, LVJr. et al. Remington: The Science and Practice of Pharmacy (Volume 2), 22nd Edition (2012), Pharmaceutical Press.

[0203] Of course, the dosage regimen of the compounds of this invention will vary according to known factors such as the pharmacodynamic characteristics of the particular agent and its mode and route of administration; the species, age, sex, health, medical condition and weight of the recipient; the nature and extent of the symptoms; kind of concurrent treatment; frequency of treatment; route of administration, the patient's renal and hepatic function and the desired effect.

[0204] As a general guide, when used for the indicated effects, the daily oral dosage of each active ingredient will range from about 0.001 to about 5000 mg / day, preferably from about 0.01 to about 1000 mg / day, and most preferably from about 0.1 to about 250 mg / day. Intravenously, during a constant rate infusion, the most preferred dosage range will be from about 0.01 to about 10 mg / kg / minute. The compounds of the invention may be administered in a single daily dose, or the total daily dose may be administered in divided doses of two, three or four times daily.

[0205] The compounds are typically administered in admixture with suitable pharmaceutical diluents, excipients or carriers (collectively referred to herein as pharmaceutical carriers) appropriately selected with respect to the intended form of administration (e.g., oral tablets, capsules, elixirs and syrups), and in accordance with conventional pharmaceutical practice.

[0206] Dosage forms (pharmaceutical compositions) suitable for administration may contain from about 1 mg to about 2000 mg of active ingredient per dosage unit. In these pharmaceutical compositions, the active ingredient will generally be present in an amount of about 0.1%-95% by weight based on the total weight of the composition.

[0207] A typical capsule for oral administration contains at least one compound of the invention (250 mg), lactose (75 mg) and magnesium stearate (15 mg).The mixture is passed through a 60 mesh screen and packaged into size L gelatin capsules.

[0208] A typical injectable formulation is produced by aseptically placing at least one compound of the invention (250 mg) into a vial, aseptically freeze-drying and sealing. When used, the contents of the vial are mixed with 2 mL of normal saline to produce an injectable formulation.

[0209] The present invention includes within its scope pharmaceutical compositions comprising a therapeutically effective amount of at least one compound of the present invention (alone or in combination with a pharmaceutical carrier) as an active ingredient. Optionally, the compounds of the present invention may be used alone, in combination with other compounds of the present invention, or in combination with one or more other therapeutic agents (e.g., anticancer agents or other pharmaceutically active materials).

[0210] Regardless of the administration route selected, the compound of the present invention (which may be used in a suitable hydrated form) and / or the pharmaceutical composition of the present invention can be formulated into a pharmaceutically acceptable dosage form by conventional methods known to those skilled in the art.

[0211] Actual dosage levels of the active ingredients in the pharmaceutical compositions of this invention may be varied so as to obtain an amount of the active ingredient that is effective to achieve a therapeutic response for a particular patient, composition, and mode of administration, without causing toxicity to the patient.

[0212] The selected dosage level will depend upon a variety of factors including the activity of the particular compound of the present invention employed, or its ester, salt or amide, the route of administration, the time of administration, the rate of excretion or metabolism of the particular compound employed, the rate and extent of absorption, the duration of the treatment, other drugs, compounds and / or materials used in combination with the particular compound employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.

[0213] A physician or veterinarian with ordinary skills in the art can easily determine and prescribe the effective amount of the desired pharmaceutical composition. For example, a physician or veterinarian can start the dosage of the compound of the present invention used in the pharmaceutical composition at a level lower than the level required to achieve a therapeutic effect, and gradually increase the dosage until the effect is achieved.

[0214] Typically, the appropriate daily dose of the compounds of this invention will be the amount of the compound that effectively produces the lowest dose of the therapeutic effect. Typically, such effective doses will depend on the factors described above. Typically, the range of oral, intravenous, intracerebroventricular and subcutaneous doses of the compounds of this invention for patients will be from about 0.01 mg to about 50 mg / kg body weight / day.

[0215] If desired, the effective daily dose of active compound may be administered as two, three, four, five, six or more sub-doses administered separately at appropriate intervals throughout the day (optionally in unit dosage form). In certain aspects of the invention, administration is once daily.

[0216] While it is possible for a compound of the present invention to be administered alone, it is preferable to administer the compound as a pharmaceutical formulation (composition).

[0217] When used in combination with the compounds of the present invention, the above other therapeutic agents can be used, for example, in the amounts indicated in the Physicians' Desk Reference (PDR) or as otherwise determined by one of ordinary skill in the art. In the methods of the present invention, one or more such other therapeutic agents can be administered before, simultaneously with, or after the administration of the compounds of the present invention.

[0218] Preparation method

[0219] The compounds of the present invention can be synthesized by a variety of methods available to those skilled in the art of organic chemistry. General synthetic schemes for preparing the compounds of the present invention are described below. These schemes are illustrative and are not intended to limit the possible techniques that a person skilled in the art can use to prepare the compounds disclosed herein. The different methods for preparing the compounds of the present invention are clear to those skilled in the art. Examples of the compounds of the present invention prepared by the methods described in the general schemes are given in the Examples section listed below. The preparation of the same chiral embodiments can be carried out by techniques known to those skilled in the art. For example, pure chiral compounds can be prepared by separating racemic products or diastereomers by chiral phase preparative HPLC. Alternatively, the example compounds can be prepared by known methods to obtain products enriched in enantiomers or diastereomers.

[0220] The reactions and techniques described in this chapter are carried out in a solvent suitable for the reagents and materials used, and are applicable to the conversions performed. In addition, in the description of the synthetic method given below, it should be understood that all proposed reaction conditions (including the selection of solvents, reaction atmosphere, reaction temperature, duration of the experiment and post-processing procedures) are selected as standard conditions for the reaction, and those skilled in the art should be easily aware of this. It should be understood by those skilled in the art of organic synthesis that the functional groups present in each part of the molecule must be compatible with the proposed reagents and reactions. Such restrictions on substituents compatible with the reaction conditions should be easily clear to those skilled in the art, wherein alternatives are required when there are incompatible substituents. This will sometimes require judgment to modify the order of the synthetic steps or select a specific method scheme rather than another, in order to obtain the desired compounds of the present invention. It will also be recognized that another major consideration in the planning of any synthetic route in this field is to judiciously select the protecting group for protecting the reactive functional groups present in the compounds described in the present invention. An authoritative explanation describing many alternatives for the trained practitioner is Wuts and Greene, Greene's Protective Groups in Organic Synthesis, 4th ed., Wiley and Sons (2007).

[0221] Example

[0222] The following examples illustrate specific and preferred embodiments of the present invention, but do not limit the scope of the present invention. Unless otherwise specified, chemical abbreviations and symbols and scientific abbreviations and symbols have their usual and customary meanings. The above defines other abbreviations used in the examples and other places in the application. Commonly used intermediates can be generally used to prepare more than one example, and are identified in order (e.g., intermediate 1, intermediate 2, etc.) and abbreviated as Int.1 or I1, Int.2 or I2, etc. The compounds of the examples are identified by the examples and steps (e.g., "1-A" represents Example 1 Step A) of preparing them or by the examples (e.g., "1" represents Example 1) of the title compounds of the examples in which only the compounds are the examples. In some cases, alternative preparations of intermediates or examples are described. Often, chemical technicians in the field of synthesis can design alternative preparations that may be desired based on one or more considerations, such as shorter reaction times, cheaper starting materials, easy to operate or separate, improve yields, be suitable for catalysis, avoid toxic reagents, the availability of special instruments, and reduce the number of linear steps, etc. The purpose of describing alternative preparations is to further enable the preparation of the embodiments of the present invention. In some cases, some of the functional groups in the outlined examples and claims may be replaced by well-known bioisosteric substitutes known in the art, such as replacement of a carboxylic acid group with a tetrazole or phosphate moiety. 1 H NMR data were processed using water suppression. The reported spectra were not corrected for water suppression. Protons adjacent to the water suppression frequency of 3.35 ppm exhibit reduced signal intensity.

[0223] abbreviation

[0224] Ac Acetyl

[0225] anhyd. anhyd

[0226] aq. Aqueous solution

[0227] Boc tert-Butyloxycarbonyl

[0228] BOP Benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate

[0229] Bu Butyl

[0230] CDI Carbonyldiimidazole

[0231] DCM Dichloromethane

[0232] DEA Diethylamine

[0233] DIEA or DIPEA Diisopropylethylamine

[0234] DMF Dimethylformamide

[0235] DMSO Dimethyl sulfoxide

[0236] dppf 1,1'-Bis(diphenylphosphino)ferrocene

[0237] Et Ethyl

[0238] EtOAc Ethyl acetate

[0239] EtOH

[0240] h, hour or hr hour

[0241] HCl

[0242] HPLC High Pressure Liquid Chromatography

[0243] LC Liquid Chromatography

[0244] LCMS liquid chromatography-mass spectrometry

[0245] M Moore

[0246] mM millimole

[0247] Me Methyl

[0248] MeOH Methanol

[0249] Mesyl-Cl Methanesulfonyl chloride

[0250] MHz Megahertz

[0251] min

[0252] M +1 (M+H) +

[0253] MS mass spectrometry

[0254] n or N positive

[0255] NH4OAc Ammonium acetate

[0256] nM nanomolar

[0257] NMP N-Methylpyrrolidone

[0258] Pd2(dba)3 tris(dibenzylideneacetone)dipalladium

[0259] pet ether petroleum ether

[0260] Ph Phenyl

[0261] POCl3 Phosphorus oxychloride

[0262] rt or Ret time retention time

[0263] sat. saturated

[0264] TEA Triethylamine

[0265] TFA Trifluoroacetic acid

[0266] THF Tetrahydrofuran

[0267] Intermediate 1

[0268] N-(4-Bromo-2-cyanophenyl)-2,2,2-trifluoroacetamide

[0269]

[0270] Triethylamine (10.61 mL, 76 mmol) and 2,2,2-trifluoroacetic anhydride (7.82 mL, 55.8 mmol) were added dropwise to a solution of 2-amino-5-bromobenzonitrile (10 g, 50.8 mmol) in THF (200 mL) at 0 ° C. The reaction mixture was stirred at room temperature for 3 h. The reaction was quenched with ice water. The reaction mixture was extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water, brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure to obtain a crude product, which was purified by silica gel column chromatography using a 24 g flash column and 20% EtOAc in petroleum ether. The fractions were concentrated under reduced pressure to obtain purified N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoroacetamide (8 g, 51.1% yield). LCMS: m / z=292.9 (M+H) + ; Retention time 1.19 min. (LCMS method: Column: Aquity UPLC BEH C18 (3.0 x 50 mm) 1.7 μm, Mobile phase A: 10 mM NH4OAc: ACN (95:5), Mobile phase B: 10 mM NH4OAc: Acetonitrile (5:95), Description: Method: % B: 0 min-20: 2 min-100: 2.3 min-100, Flow rate: 0.7 ml / min; Detection: UV at 220 nm). 1 H NMR (400 MHz, CHLOROFORM-d) δ (ppm) 8.30-8.28 (m, 2H), 7.85-7.80 (m, 2H).

[0271] Intermediate 2

[0272] N-(4-Bromo-2-cyanophenyl)-2,2,2-trifluoro-N-methylacetamide

[0273]

[0274] To a solution of N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoroacetamide (8 g, 27.3 mmol) in DMF (25 mL) at room temperature was added potassium carbonate (9.43 g, 68.2 mmol) followed by methyl iodide (8.54 mL, 136 mmol). The reaction mixture was stirred at room temperature for 16 h. The reaction mixture was quenched with water and extracted with ethyl acetate (2 x 100 mL). The combined organic layers were washed with water, brine, and dried over sodium sulfate. The solvent was evaporated under reduced pressure to give N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoro-N-methylacetamide (6 g, 71.6% yield). LCMS: m / z=213.0 (M-COCF3+H) + ; Retention time 1.57 min. (Column: Aquitey UPLC BEH C18 (3.0 x 50 mm) 1.7 μm, Phase A: 10 mM NH4OAc:ACN (95:5), Mobile phase B: 10 mM NH4OAc:ACN (5:95), Description: Method: %B: 0 min-20: 2 min-100: 2.3 min-100, Flow rate: 0.7 mL / min.

[0275] Intermediate 3

[0276] 5-Bromo-2-(methylamino)benzamide

[0277]

[0278] To a solution of N-(4-bromo-2-cyanophenyl)-2,2,2-trifluoro-N-methylacetamide (8 g, 26.1 mmol) in DMSO (80 mL) / water (40 mL) at 0°C was added KCO (7.2 g, 52.1 mmol), followed by dropwise addition of hydrogen peroxide (37%, 10.73 mL, 105 mmol) over a period of 10 minutes. The reaction mixture was stirred at room temperature for 2 hours and then quenched with ice water. The solid was isolated by filtration, and washed with water and dried under reduced pressure to give 5-bromo-2-(methylamino)benzamide (4 g, 59.0% yield). LCMS: m / z=229.1 (M+H) + ; Retention time 1.14min. Mobile phase A: 10mM NH4OAc:ACN (95:5), mobile phase B: 10mM NH4OAc:ACN (5:95), method: %B: 0min-20%: 1.1min-90%: 1.7min-90%, column name: Aquity UPLC BEH18 (3.0x50mm), 1.7μm, flow rate: 0.7mL / min.

[0279] Intermediate 4

[0280] 6-Bromo-1-methylquinazoline-2,4(1H,3H)-dione

[0281]

[0282] To a solution of 5-bromo-2-(methylamino)benzamide (4 g, 17.46 mmol) in N,N-dimethylformamide (40 mL) was added NaH (1.379 g, 34.9 mmol, 60% w / w) at 0°C. The reaction mixture was stirred at room temperature for 1 hour. A solution of CDI (4.25 g, 26.2 mmol) in dimethylformamide (5 mL) was added, and the reaction mixture was heated at 70°C for 2 h. The reaction mixture was cooled to room temperature. The solid product was isolated by filtration, washed with water and dried under reduced pressure to give 6-bromo-1-methylquinazoline-2,4 (1H, 3H) -dione (3 g, 67.4% yield). LCMS: m / z = 255.0 (M + H); retention time 0.91 min. (Column: Aquity UPLC BEH C18 (3.0 x 50 mm) 1.7 μm, mobile phase A: 10 mM NH4OAc:ACN (95:5), mobile phase B: 10 mM NH4OAc:ACN (5:95), method: %B: 0 min-20: 2 min-100: 2.3 min-100, flow rate: 0.7 mL / min). 1 H NMR (DMSO-d6, 400MHz): δ (ppm) 11.70 (br s, 1H), 8.04 (d, J = 2.4Hz, 1H), 7.91 (dd, J = 8.8, 2.4Hz, 1H), 7.40 (d, J = 9.0Hz, 1H), 3.43 (s, 3H).

[0283] Intermediate 5

[0284] 6-Bromo-4-chloro-1-methylquinazolin-2(1H)-one

[0285]

[0286] To a suspension of 6-bromo-1-methylquinazoline-2,4(1H,3H)-dione (1 g, 3.92 mmol) in dry toluene (30 mL) was added DIPEA (1.712 mL, 9.80 mmol) and POCl3 (1.827 mL, 19.60 mmol) at room temperature. The reaction mixture was heated at 110°C for 16 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure to give 6-bromo-4-chloro-1-methylquinazoline-2(1H)-one (1 g, 41.0% yield). LCMS: m / z=273.0 (M+H) + ; Retention time 1.71 min. (LCMS method: column-Kinetex XB-C18 (75X3mm-2.6μm), mobile phase A: 10mM NH4COOH:ACN in water (98:2), mobile phase B: 10mM NH4COOH:ACN in water (2:98).

[0287] Intermediate 6

[0288] (2R,5S)-tert-Butyl 4-(6-bromo-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate

[0289]

[0290] To a stirred solution of (2R,5S)-2-ethyl-5-methylpiperazine-1-carboxylic acid tert-butyl ester (CAS# 2165403-17-6) (1 g, 3.48 mmol) in acetonitrile (20 mL) was added DIPEA (6.08 mL, 34.8 mmol). The reaction mixture was stirred at room temperature for 15 min. 6-bromo-4-chloro-1-methylquinazolin-2(1H)-one (0.952 g, 3.48 mmol) was added to the reaction mixture. The reaction mixture was heated at 85 °C for 6 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure to obtain the crude product, which was purified by silica gel column chromatography (60%-70% EtOAc / petroleum ether; 40 g column) to give (2R,5S)-tert-butyl 4-(6-bromo-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate (0.8 g, 33.6%). LCMS: m / z=467.2 (M+H); retention time 1.74 min. LCMS method: Column: Waters AcquityUPLC BEH C18 (2.1x50mm) 1.7μm, Mobile phase A: 10mM ammonium acetate:acetonitrile (95:5); Mobile phase B: 10mM ammonium acetate:acetonitrile (5:95), Gradient = 20% B over 1.1 minutes, then hold at 100% B for 2.2 minutes; Temperature: 50°C; Flow rate: 0.7mL / min; Detection: UV at 110nm).

[0291] Intermediate 7

[0292] (2R,5S)-tert-Butyl 4-(6-cyano-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate

[0293]

[0294] Zinc cyanide (0.151 g, 1.289 mmol) and zinc (0.042 g, 0.645 mmol) were added to a stirred solution of (2R, 5S)-4-(6-bromo-1-methyl-2-oxo-1,2-dihydroquinazoline-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylic acid tert-butyl ester (0.3 g, 0.645 mmol) in NMP (2 mL). The reaction mixture was degassed for 5 min, then Pd2(dba)3 (0.059 g, 0.064 mmol), dppf (0.071 g, 0.129 mmol) were added and heated at 90 ° C overnight. The reaction mixture was cooled to room temperature, diluted with ethyl acetate and filtered through a celite pad. The filtrate was washed with water and brine, and the organic layer was dried over anhydrous Na2SO4, filtered and evaporated under reduced pressure to obtain a crude compound. The crude compound was purified by silica gel chromatography (70%-80% EtOAc / petroleum ether; 24 g column) to give tert-butyl (2R,5S)-4-(6-cyano-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylate (0.23 g, 63.3% yield) LCMS: m / z=412.3 (M+H) + ; Retention time 0.65 min. LCMS method: Column: Waters Acquity UPLC BEH C18 (2.1x50 mm) 1.7 μm, Mobile phase A: 10 mM ammonium acetate: acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate: acetonitrile (5:95), Gradient = 20% B over 1.1 min, then hold at 100% B for 2.2 min; Temperature: 50°C; Flow rate: 0.7 mL / min Detection: UV at 110 nm.

[0295] Intermediate 8

[0296] 4-((2S,5R)-5-ethyl-2-methylpiperazin-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile

[0297]

[0298] To a stirred solution of (2R,5S)-4-(6-cyano-1-methyl-2-oxo-1,2-dihydroquinazolin-4-yl)-2-ethyl-5-methylpiperazine-1-carboxylic acid tert-butyl ester (0.1 g, 0.243 mmol) in dry DCM (5 mL) was added TFA (0.281 mL, 3.65 mmol) at room temperature. The reaction mixture was stirred for 3 h. The solvent was removed under reduced pressure to give 4-((2S,5R)-5-ethyl-2-methylpiperazin-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile, TFA (0.1 g, 0.202 mmol, 83% yield). LCMS: m / z=312.2 (M+H) + ; Retention time 0.68 min. LCMS method: Column: Waters AcquityUPLC BEH C18 (2.1x50 mm) 1.7 μm, Mobile phase A: 10 mM ammonium acetate: acetonitrile (95:5); Mobile phase B: 10 mM ammonium acetate: acetonitrile (5:95), Gradient = 20% B over 1.1 min, then hold at 100% B for 2.2 min; Temperature: 50°C; Flow rate: 0.7 mL / min; Detection: UV at 110 nm).

[0299] Examples 1 and 2

[0300] 4-((2S,5R)-5-ethyl-2-methyl-4-(1-(4-(trifluoromethyl)phenyl)ethyl)piperazin-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile

[0301]

[0302] To a solution of 4-((2S,5R)-5-ethyl-2-methylpiperazine-1-yl)-1-methyl-2-oxo-1,2-dihydroquinazoline-6-carbonitrile, TFA (0.2 g, 0.47 mmol) in acetonitrile (5 mL) at room temperature, DIPEA (0.246 mL, 1.410 mmol) was added. The reaction mixture was heated at 85 ° C for 15 min. Next, 1-(1-chloroethyl)-4-(trifluoromethyl)benzene (0.196 g, 0.940 mmol) (CAS-85289-90-3) and sodium iodide (0.07 g, 0.47 mmol) were added to the reaction mixture. The reaction mixture was heated at 85 ° C for 16 h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate (100 mL). The organic layer was washed with brine, dried over Na2SO4 and concentrated under reduced pressure to give the crude product as a mixture of diastereomers, which was purified by preparative HPLC [HPLC method: Column: EVO C18 (20x250mm), 5μm, mobile phase A-10mM ammonium bicarbonate B: ACN / MeOH, flow rate: 20mL, to produce Peak 1 (Example 1) and Peak 2 (Example 2).

[0303] Fraction 1 (peak 1) was concentrated under reduced pressure, and the residue was diluted with (EtOH / H2O, 1:5) and lyophilized to give Example 1 (6 mg, 2.6% yield); LCMS: m / z=484.3 (M+H) + ; Retention time 2.249min; (LCMS method: column: XBridge BEH XP C18 (50x2.1mm), 2.5μm; mobile phase A: 95% water: 5% acetonitrile; 10mM ammonium acetate; mobile phase B: 5% water: 95% acetonitrile; 10mM ammonium acetate; flow rate: 1.1mL / min; temperature: 50℃; time (min): 0-3; %B: 0-100%). 1H NMR(400MHz,DMSO-d6)δ8.16(d,J=1.7Hz,1H),8.04(dd,J=8.8,1.7Hz,1H),7.76-7.68( m,2H),7.62(d,J=8.1Hz,2H),7.53(d,J=8.8Hz,1H),4.77-4.66(m,1H),3.97-3.88(m,1 H),3.88-3.79(m,1H),3.64-3.57(m,1H),3.45(s,3H),2.91-2.84(m,1H),2.82-2.74(m ,1H),2.37-2.32(m,1H),1.44(d,J=6.6Hz,3H),1.35-1.24(m,5H),0.48(t,J=7.5Hz,3H)

[0304] Fraction 2 (peak 2) was concentrated under reduced pressure, and the residue was diluted with (EtOH / H2O, 1:5) and lyophilized to produce Example 2 (0.07 g, 0.144 mmol, 10.27% yield); LCMS: m / z=484.3 (M+H); retention time 2.27 min; (LCMS method: column: XBridge BEH XP C18 (50x2.1 mm), 2.5 μm; mobile phase A: 95% water: 5% acetonitrile; 10 mM ammonium acetate; mobile phase B: 5% water: 95% acetonitrile; 10 mM ammonium acetate; flow rate: 1.1 mL / min; temperature: 50°C; time (min): 0-3; %B: 0-100 1 H NMR(400MHz,DMSO-d6)δppm 8.15(d,J=1.7Hz,1H),8.05(dd,J=8.8,1.7Hz,1H),7.76-7.66(m,2H),7.66-7.57(m,2H),7.54(d,J=9.0Hz,1H),4.57-4.47(m,1H),4.16(br d,J=13.4Hz,1H),3.79-3.67(m,2H),3.45(s,3H),3.11-3.02(m,1H),2.74-2.67(m,1H),2.12( dd,J=12.0,2.0Hz,1H),1.54-1.41(m,2H),1.26(dd,J=6.4,3.4Hz,6H),0.78(t,J=7.5Hz,3H).

[0305] Bioassay

[0306] The pharmacological properties of the compounds of the invention can be confirmed by a number of biological assays. The following exemplary biological assays have been performed with the compounds of the invention.

[0307] Assay 1: In vitro DGK inhibition assay - Method A

[0308] DGKα and DGKζ reactions were performed using either extruded liposomes (DGKα and DGKζ LIPGLO assay) or detergent / lipid micelle substrates (DGKα and DGKζ assays). Reactions were performed in 50 mM MOPS pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 μM CaCl2, and 1 mM DTT (assay buffer). Reactions using detergent / lipid micelle substrates also contained 50 mM octyl BD-pyranoglucoside. For detergent / lipid micelle reactions, lipid substrate concentrations were 11 mM PS and 1 mM DAG. For extruded liposome reactions, lipid substrate concentrations were 2 mM PS, 0.25 mM DAG, and 2.75 mM PC. Reactions were performed in 150 μM ATP. Enzyme concentrations for DGKα and DGKζ were 5 nM.

[0309] Compound inhibition study is carried out as follows: 50nL droplets of each test compound dissolved in DMSO (for each compound, the highest concentration 10mM, 11 points of continuous 3-fold dilution multiples) are transferred to the hole of white 1536-well plate (Corning3725). By merging 2.5mL 4x enzyme solution (20nM DGKα or DGKζ (prepared as described below) in assay buffer) and 2.5mL 4x liposomes or 4x detergent / lipid micelle solution (composition is described below) to prepare 5mL enzyme / substrate solution (2x final reaction concentration) and incubate it at room temperature for 10 minutes. Next, 1 μL 2x enzyme / substrate solution is added to the hole containing the test compound and by adding 1 μL 300uM ATP to start the reaction. Allow the reaction to carry out 1h, thereafter add 2 μL Glo reagent (Promega V9101) and incubate 40 minutes. Next, add 4 μL kinase detection reagents and incubate 30 minutes. Luminescence was recorded using an EnVision microplate reader. Percent inhibition was calculated from ATP conversion produced by no enzyme control reactions (100% inhibition) and ATP conversion produced by vehicle-only reactions (0% inhibition). Compounds were evaluated at 11 concentrations to determine the IC 50 .

[0310] Preparation of 4x detergent / lipid micelles

[0311] Detergent / lipid micelles are prepared in the following manner: 15 g phosphatidylserine (Avanti 840035P) and 1 g diacylglycerol (800811O) are merged and dissolved in the 150 mL chloroform in a 2 L round bottom flask. Chloroform is removed under high vacuum by rotary evaporation. The colorless viscous oily substance of gained is resuspended in 400 mL 50 mM MOPS pH 7.5, 100 mM NaCl, 20 mM NaF, 10 mM MgCl , 1 μM CaCl , 1 mM DTT and 200 mM octyl glucoside by vigorous mixing. The lipid / detergent solution is divided into 5 mL aliquots and stored at -80°C.

[0312] 4x Liposome Preparation

[0313] Lipid composition is 5mol% DAG (Avanti 800811O), 40mol% PS (Avanti 840035P) and 55mol% PC (Avanti 850457), and the total lipid concentration for 4x liposome solution is 15.2mg / mL. PC, DAG and PS are dissolved in chloroform, merged, and dried into a film in a vacuum. Lipid is hydrated to 20mM in 50mM MOPS pH 7.5, 100mM NaCl, 5mM MgCl2, and freeze-thawed five times. The lipid suspension is extruded 11 times through a 100nm polycarbonate filter. Dynamic light scattering is carried out to confirm the size of the liposome (radius is 50-60nm). The liposome preparation is stored at 4°C for up to 4 weeks.

[0314] Baculovirus expression of human DGKα and DGKζ

[0315] Human DGK-α-TVMV-His-pFBgate and human DGK-ζ-transcription variant-2-TVMV-His-pFBgate baculovirus samples were generated using the Bac-to-Bac baculovirus expression system (Invitrogen) according to the manufacturer's protocol. The DNA used to express DGK-α and DGK-ζ has SEQ ID NO: 1 and 3, respectively. Baculovirus amplification was achieved using infected Sf9 cells at a virus / cell ratio of 1:1500 and grown at 27°C for 65 hours after transfection.

[0316] Amplification of expression of each protein was performed in a Cellbag 50L WAVE-Bioreactor system 20 / 50 from GE Healthcare Bioscience. 12L of 2 × 10 6Sf9 cells (Expression System, Davis, CA) grown in ESF921 insect medium (Expression System) at 1:200 virus / cell ratio were infected with virus stocks and grown at 27°C for 66-68 hours post infection. Infected cell cultures were harvested by centrifugation at 2000 rpm for 20 min at 4° C. in a RC12BP centrifuge. Cell pellets were stored at −70° C. until purification.

[0317] Purification of human DGK-α and DGK-ζ

[0318] Full-length human DGKα and DGKζ (each expressed with a TVMV-cleavable C-terminal Hexa-His tag sequence (SEQ ID NOs: 2 and 4, respectively) and produced as described above) were purified from insect cell paste infected with Sf9 baculovirus. Cells were lysed by nitrogen cavitation using a nitrogen bomb (Parr Instruments) and the lysate was clarified by centrifugation. The clarified lysate was purified to about 90% homogeneity using three consecutive column chromatography steps on the Purifier Plus system. This three-step column chromatography includes nickel affinity resin capture (i.e., HisTrap FF crude, GE Healthcare), followed by size exclusion chromatography (i.e., HiLoad 26 / 600 Superdex 200 preparative grade for DGK-α, GE Healthcare, and HiPrep 26 / 600 Sephacryl S 300_HR for DGK-ζ, GE Healthcare). The third step is ion exchange chromatography, and is different for the two isotypes. DGKα was refined using Q-Sepharose anion exchange chromatography (GE Healthcare). DGKζ was refined using SP Sepharose cation exchange chromatography (GE Healthcare). Protein was delivered at a concentration of ≥2 mg / mL. The formulation buffer for both proteins was identical: 50 mM Hepes, pH 7.2, 500 mM NaCl, 10% v / v glycerol, 1 mM TCEP, and 0.5 mM EDTA.

[0319] Assay 2: In vitro DGK inhibition assay - Method B

[0320] DGKα and DGKζ reactions were performed using either extruded liposomes (DGKα and DGKζ LIPGLO assay) or detergent / lipid micelle substrates (DGKα and DGKζ assays). Reactions were performed in 50 mM MOPS pH 7.5, 100 mM NaCl, 10 mM MgCl2, 1 μM CaCl2, and 1 mM DTT (assay buffer). Reactions using detergent / lipid micelle substrates also contained 50 mM octyl BD-pyranoglucoside. For detergent / lipid micelle reactions, lipid substrate concentrations were 11 mM PS and 1 mM DAG. For extruded liposome reactions, lipid substrate concentrations were 2 mM PS, 0.25 mM DAG, and 2.75 mM PC (5 mM total lipids). Reactions were performed in 150 μM ATP. Enzyme concentrations for DGKα and DGKζ were 5 nM.

[0321] Compound inhibition study is carried out as follows: 25nL droplets of each test compound dissolved in DMSO (for each compound, the highest concentration 10mM, 11 points of continuous 3-fold dilution multiples) are transferred to the hole of white 1536-well plate (Corning3725). By merging 2.5mL 4x enzyme solution (20nM DGKα or DGKζ (prepared as described below) in assay buffer) and 2.5mL 4x liposome or 4x detergent / lipid micelle solution (composition is described below) to prepare 5mL enzyme / lipid substrate solution (2x final reaction concentration) and it is incubated at room temperature for 10 minutes. Next, 1 μL 2x enzyme / lipid substrate solution is added to the hole containing the test compound and by adding 1 μL 300uM ATP to start the reaction. Allow the reaction to carry out 2h, thereafter add 2 μL Glo reagent (Promega V9101) and incubate 40 minutes. Next, add 4 μL kinase detection reagents and incubate 30 minutes. Luminescence was recorded using an EnVision microplate reader. Percent inhibition was calculated from ATP conversion produced by no enzyme control reactions (100% inhibition) and ATP conversion produced by vehicle-only reactions (0% inhibition). Compounds were evaluated at 11 concentrations to determine the IC 50 .

[0322] Preparation of 4x detergent / lipid micelles

[0323] Detergent / lipid micelles are prepared in the following manner: 15 g phosphatidylserine (Avanti 840035P) and 1 g diacylglycerol (800811O) are merged and dissolved in the 150 mL chloroform in a 2 L round bottom flask. Chloroform is removed under high vacuum by rotary evaporation. The colorless viscous oily substance of gained is resuspended in 400 mL 50 mM MOPS pH 7.5, 100 mM NaCl, 20 mM NaF, 10 mM MgCl , 1 μM CaCl , 1 mM DTT and 200 mM octyl glucoside by vigorous mixing. The lipid / detergent solution is divided into 5 mL aliquots and stored at -80°C.

[0324] 2x Liposome Preparation

[0325] Lipid composition is 5mol% DAG (Avanti 800811O), 40mol% PS (Avanti 840035P) and 55mol% PC (Avanti 850457), and the total lipid concentration for the liposome solution is 7-8mg / mL. PC, DAG and PS are dissolved in chloroform, merged, and dried into a film in a vacuum. Lipid is hydrated to 20mM in 50mM MOPS pH 7.5, 100mM NaCl, 5mM MgCl2, and freeze-thawed five times. The lipid suspension is extruded through a 100nm polycarbonate filter 10-12 times. Dynamic light scattering is performed to confirm the size of the liposome (radius is 50-60nm). The liposome preparation is stored at 4°C for up to 4 weeks.

[0326] Baculovirus expression of nearly full-length human DGKα and full-length DGKζ

[0327] Human MA-hDGKα-(S9-S727)-Ct-TVMV-His-pFBgate and full-length human DGK-ζ-transcript variant-2-TVMV-His-pFBgate baculovirus samples were generated using the Bac-to-Bac baculovirus expression system (Invitrogen) according to the manufacturer's protocol (Note: The MA in the DGKα reagent name indicates two additional amino acids added before Ser-9). The DNA used to express DGK-α (9-727) and DGK-ζ has SEQ ID NOs: 5 and 3, respectively. Baculovirus amplification was achieved using infected Sf9 cells at a virus / cell ratio of 1:1500 and grown at 27°C for 65 hours after transfection.

[0328] The expression of nearly full-length DGK-α(9-727) protein was scaled up in 2L flasks, and full-length DGKζ was achieved using the Cellbag 50L WAVE-bioreactor system 20 / 50 from GE Healthcare Bioscience. Similar conditions were used to express proteins at different volumes. For the expression of DGKα(9-727), 2x2L flasks were used, each containing 0.8L final volume of medium, and DGKζ was grown at 12L scale in a 50L Cellbag. For each, an initial density of 2×10 6 Sf9 cells (Expression System, Davis, CA) at 10 cells / mL were inoculated in ESF921 insect vector (Expression System), infected with virus stock at a virus / cell ratio of 1:200, and grown at 27°C for 66-68 hours post infection. Infected cell cultures were harvested by centrifugation at 2000 rpm for 20 min at 4° C. in a RC12BP centrifuge. Cell pellets were stored at −80° C. until purification.

[0329] Purification of human DGK-α and DGK-ζ

[0330] Human DGKα(9-727) and full-length DGKζ (each expressed with a TVMV-cleavable C-terminal Hexa-His tag sequence (SEQ ID NO: 2 and 4, respectively) and produced as described above) were purified from insect cell paste infected with Sf9 baculovirus. The cell paste was thawed and suspended in buffer (50 mM HEPES (pH 7.2), 300 mM NaCl, 10% v / v glycerol, 1 mM TCEP, containing benzonase and protease inhibitors) to 1:10 v / v of the original culture volume. Lysis was accomplished using nitrogen cavitation with a nitrogen bomb (Parr Instruments), and the lysate was clarified by centrifugation. The lysate of clarification is purified to about 90% uniformity using two or three continuous column chromatography steps on the Purifier Plus system. By nickel affinity purification with imidazole gradient elution (i.e., HisTrap FF, GE Healthcare), then size exclusion chromatography (i.e., for DGKα (9-727), HiLoad 26 / 600Superdex 200 preparative grade, GE Healthcare, and for DGKζ, HiPrep 26 / 600Sephacryl S 300HR, GE Healthcare) to purify two isoforms. These two steps produce DGKα (9-727) with a purity of> 90%. Achieving similar purity of full-length DGKζ requires the third step, using cation exchange chromatography (SP Sepharose FF, GE Healthcare), and eluting with NaCl gradient. The final formulation buffer for both proteins was similar, with DGKα(9-727) prepared in 50 mM Hepes (pH 7.3), 300 mM NaCl, 10% v / v glycerol and 1 mM TCEP, and full-length DGKζ prepared in 50 mM Hepes (pH 7.3), 500 mM NaCl, 5% v / v glycerol and 1 mM TCEP. The proteins were concentrated to 1-2 mg / mL, snap frozen, and stored long term at -80°C.

[0331] Assay 3: Raji CD4 T cell IL2 assay

[0332] 1536-well IL-2 assay was performed using pre-activated CD4 T cells and Raji cells in a 4 μL volume. Before the assay, CD4 T cells were pre-activated by treatment with 1.5 μg / mL, 1 μg / mL and 10 μg / mL of α-CD3, α-CD28 and PHA, respectively. Raji cells were treated with 10,000 ng / mL of staphylococcal enterotoxin B (SEB). First, the serially diluted compounds were transferred to a 1536-well assay plate (Corning, #3727), followed by addition of 2 μL pre-activated CD4 T cells (final density of 6000 cells / well) and 2 μL of SEB-treated Raji cells (2000 cells / well). After culturing in a 37°C / 5% CO2 incubator for 24 hours, 4 μl IL-2 detection reagents were added to an assay plate (Cisbio, #64IL2PEC). The assay plate was read on an Envision reader. To evaluate the cytotoxicity of the compounds, Raji or CD4 T cells were incubated with serially diluted compounds. After 24 hours of incubation, 4 μL Cell Titer Glo (Promega, #G7572) was added and the plates were read on an Envision reader. The 50% effective concentration (IC) was calculated using the four-parameter logistic formula y = A + ((BA) / (1 + ((C / x)^D))) 50 ), where A and B represent the minimum and maximum activation or inhibition, respectively, and C is the IC 50 , D is the slope and x represents the compound concentration.

[0333] Assay 4: CellTiter-Glo CD8 T Cell Proliferation Assay

[0334] Frozen naive human CD8 T cells were thawed in RPMI+10% FBS, incubated at 37°C for 2h, and counted. 384-well tissue culture plates were coated with 20μl of 0.1μg / mL anti-human CD3 in ordinary RPMI at 4°C overnight, removed from the plate, and then 20k / 40μL CD8 T cells (with 0.5μg / ml soluble anti-human CD28) were added to each well. Immediately after cell plating, the compound was added (echoed) to the cell plate with an echo instrument. After 72h of culture in a 37°C incubator, 10μL CellTiter-glo reagent (Promega catalog number G7570) was added to each well. The plate was shaken vigorously for 5min, incubated for another 15min at room temperature, and CD8 T cell proliferation was read on Envision. In the analysis, 0.1μg / mL anti-CD3 and 0.5μg / mL anti-CD28 stimulated CD8 T cell signals were background. The 100% range was set using 3 μM of the reference compound 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile, and the EC 50 The data were normalized at the absolute 50%.

[0335] Assay 5: DGK AP1-reporter gene assay

[0336] The Jurkat AP1-luciferase reporter was generated using the Cignal Lenti AP1 Reporter (luc) Kit (CLS-011L) from SABiosciences.

[0337] Compounds were transferred from the Echo LDV plate to individual wells of a 384-well plate (white, solid bottom, opaque PE CulturPlate 6007768) using an Echo550 instrument. Sample volume was 30 nL / well; and one destination plate per source plate. Cell suspensions were prepared by transferring 40 mL of cells (2x20 mL) to a clean 50 mL conical tube. Cells were concentrated by centrifugation (1200 rpm; 5 min; ambient temperature). The supernatant was removed and all cells were suspended in RPMI (Gibco 11875) + 10% FBS to a concentration of 1.35 x 10 6 Cells (30 μL cell suspension / well) were manually added to the 384-well TC plates containing compounds using a multichannel pipette, 4.0x10 4 The cell plate was incubated at 37°C and 5% CO2 for 20 minutes.

[0338] During the incubation, an anti-CD3 antibody (αCD3) solution was prepared by mixing 3 μL aCD3 (1.3 mg / mL) with 10 mL of culture medium [final concentration = 0.4 μg / mL]. Next, 1.5 μl aCD3 (1.3 mg / mL) was mixed with 0.5 mL of culture medium [final concentration = 4 μg / ml]. After 20 minutes, 10 μL of culture medium was added to all wells in column 1 (wells A to M), and 10 μL of αCD3 (4 ug / mL) was added to each well in column 1 (rows N to P) for reference. 10 μL of αCD3 (0.4 ug / mL) was then added to each well using a multichannel pipette. αCD3 stimulated + / - compound treated cells were incubated at 37°C 5% CO2 for 6 hours.

[0339] During this incubation period, Steady-Glo (Promega E2520) reagent was slowly thawed to ambient temperature. Next, 20 μL Steady-Glo reagent / well was added using a multi-drop Combi-dispenser. Bubbles were removed by centrifugation (2000 rpm, ambient temperature, 10 seconds). The cells were incubated at room temperature for 5 minutes. The samples were characterized by measuring relative light units (RLU) according to the luminescence protocol using an Envision plate reader. The reference compound 8-(4-(bis(4-fluorophenyl)methyl)piperazine-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile was used to analyze the data to normalize 100% inhibition.

[0340] Assay 6: Murine Cytotoxic T Lymphocyte Assay

[0341] An antigen-specific cytolytic T cell (CTL) assay was developed to functionally evaluate the ability of DGKα and DGKζ inhibitors to enhance effector T cell-mediated tumor cell killing activity. CD8+ T cells isolated from OT-1 transgenic mice recognized antigen-presenting cells MC38, which presented the ovalbumin-derived peptide SIINFEKL. Recognition of cognate antigen initiated the cytolytic activity of OT-1 antigen-specific CD8+ T cells.

[0342] Functional CTL cells were generated as follows: OT-1 splenocytes were isolated from 8-12 week old mice and amplified in the presence of 1 μg / mL of SIINFEKL peptide and 10U / mL of mIL2. Three days later, fresh culture medium with mIL2 U / ml was added. On the 5th day of amplification, CD8+ T cells were isolated and ready for use. Activated CTL cells can be stored frozen for 6 months. Separately, one million MC38 tumor cells were pulsed with 1 μg / mL of SIINFEKL-OVA peptide at 37°C for 3 hours. The cells were washed with fresh culture medium (3X) to remove excess peptides. Finally, CTL cells pretreated with DGK inhibitor for 1 hour in a 96-well U-bottom plate were merged with MC38 tumor cells loaded with antigen at a ratio of 1:10. The cells were then rotated at 700rpm for 5min and placed in an incubator overnight at 37°C. After 24 hours, supernatants were collected for analysis of IFN-γ cytokine levels using AlphaLisa purchased from Perkin Elmer.

[0343] Assay 7: PHA proliferation assay

[0344] Phytohemagglutinin (PHA) stimulated embryonic cells from frozen stocks were incubated in RPMI medium (Gibco, ThermoFisher Scientific, Waltham, MA) supplemented with 10% fetal bovine serum (Sigma Aldrich, St. Louis, MO) for 1 hour and then added to individual wells (10,000 cells / well) of 384-well plates. Compounds were transferred to individual wells of 384-well plates and treated cells were maintained in medium containing human IL2 (20 ng / mL) at 37°C 5% CO2 for 72 h before growth was measured using MTS reagent [3-(4,5-dimethyl-2-yl)-5-(3-carboxymethyloxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] according to the manufacturer's instructions (Promega, Madison, WI). Percent inhibition was calculated by comparing values ​​between IL2 stimulation (0% inhibition) and unstimulated controls (100% inhibition). The inhibitory concentration (IC) was calculated based on the 50% inhibition of IL2-stimulated versus unstimulated treatment. 50 ) determination.

[0345] Assay 8: Human CD8 T cell IFN-γ assay

[0346] Frozen naive human CD8 T cells were thawed in AIM-V medium, incubated at 37°C for 2h, and counted. 384-well tissue culture plates were coated overnight at 4°C with 20 μL of 0.05 μg / mL anti-human CD3 in PBS, removed from the plate, and 40,000 cells / 40 microliters of CD8 T cells (with 0.1 μg / mL soluble anti-human CD28) were added to each well. After cell plating, the compound was immediately transferred to the cell plate using an Echo liquid handler. After incubation in a 37°C incubator for 20h, 3 microliters / well of supernatant was transferred to a new 384-well white assay plate for cytokine measurement.

[0347] Interferon-γ (IFN-γ) was quantified using the AlphLISA kit (Catalog No. AL217) as described in the manufacturer's manual (Perkin Elmer). The counts from each well were converted to IFN-γ concentrations (pg / mL). Compound EC was determined by setting 0.05 μg / mL of anti-CD3 + 0.1 μg / mL of anti-CD28 as the baseline and setting the costimulation of 3 μM reference compound 8-(4-(bis(4-fluorophenyl)methyl)piperazine-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile with anti-CD3 + anti-CD28 as 100% activation. 50 value.

[0348] Assay 9: Human CD8 T cell pERK assay

[0349] Frozen naive human CD8 T cells were thawed in AIM-V medium, incubated at 37°C for 2h, and counted. CD8 positive T cells were added to 384-well tissue culture plates at 20,000 cells / well in AIM-V medium. A compound was added to each well, and then bead-bound anti-human CD3 and anti-CD28 mAbs were added at a final concentration of 0.3 μg / mL. The cells were incubated at 37°C for 10 minutes. The reaction was terminated by adding lysis buffer from the AlphaLISA Surefire kit. (Perkin Elmer, catalog number ALSU-PERK-A). The lysate (5 μL / well) was transferred to a new 384-well white assay plate for pERK activation measurement.

[0350] Anti-CD3 + anti-CD28 was set as baseline and costimulation of 3 μM 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile with anti-CD3 + anti-CD28 was set as 100% activation to determine compound EC 50 .

[0351] Assay 10: Human whole blood IFN-γ assay

[0352] Human venous whole blood (22.5 μL / well) obtained from healthy donors was pretreated with compounds for one hour at 37° C. in a humidified 95% air / 5% CO2 incubator. The blood was stimulated with 2.5 μL of anti-human CD3 and anti-CD28 mAbs, each at a final concentration of 1 μg / mL, at 37° C. for 24 hours. IFN-γ in the supernatant was measured using the AlphLISA kit (Cat# AL217).

[0353] Compound EC was determined by setting anti-CD3 + anti-CD28 as baseline and co-stimulation of 3 μM reference compound 8-(4-(bis(4-fluorophenyl)methyl)piperazin-1-yl)-5-methyl-7-nitro-6-oxo-5,6-dihydro-1,5-naphthyridine-2-carbonitrile with anti-CD3 + anti-CD28 as 100% activation. 50 .

[0354] Assay 11: DGK Human Whole Blood pERK Assay

[0355] Human whole blood ERK phosphorylation assay was performed with human venous whole blood obtained from healthy donors (with heparin as anticoagulant). Compound serial dilutions (11 points, 3 times) in DMSO were added to 384-well plates at 20 nL / well using an ECHO 550 acoustic dispenser (Labcyte) to reach a final starting concentration of 20 μM in the assay. Heparinized human whole blood was added to the compound plate at 9 μL / well and incubated at 37°C for one hour in a humidified 95%, air / 5% CO2 incubator. After one hour of compound incubation, 1 μL of human anti-CD3 antibody (in-house) in the presence of cross-linked antibody goat anti-mouse IgG (4 μg / mL) was added to the wells at a final concentration of 1 μg / mL to stimulate the pathway, and incubated for an additional 15 minutes at 37°C. Stimulation was stopped by adding 90 μL of Fix / Lyse buffer (BD 558049). The cells were washed and stained with anti-CD8 PE (BD 555635) antibody for 60 minutes at room temperature, washed again, and permeabilized using Perm III buffer (BD 558050) on ice for 30 minutes. 647 anti-ERK1 / 2 Phospho (Thr202 / Tyr204) antibody (Bioleged 675504) was used for staining at a dilution of 1:50 for 60 minutes. The samples were washed and resuspended in dPBS containing 1% BSA (dPBS, Gibco 14190136; BSA, Sigma-Aldrich A9205). Samples were analyzed by iQue Screener PLUS. pERK activation was quantified by the percentage of pERK positive population in the CD8 positive population. Compound potency was calculated based on 20 μM concentration of internal compound as 100% activation and anti-CD3 control as 0% activation.

[0356] Nucleotide sequence encoding hDGKα-(M1-S735)-Ct-TVMV-His:

[0357]

[0358]

[0359] The amino acid sequence of hDGKα-(M1-S735)-Ct-TVMV-His:

[0360]

[0361] Nucleotide sequence encoding hDGKζ-(M1-A928)-transcription variant-2Ct-TVMV-His:

[0362]

[0363]

[0364] The amino acid sequence of hDGKζ-(M1-A928)-transcription variant-2Ct-TVMV-His:

[0365]

[0366]

[0367] Nucleotide sequence encoding MA-hDGKα-(S9-S727)-Ct-TVMV-His:

[0368]

[0369]

[0370]

[0371] AND -Amino acid sequence of hDGKα-(S9-S727)-Ct-TVMV-His:

[0372] Sequence Listing <110> Bristol-Myers Squibb <120> Substituted quinazoline compounds useful as T cell activators <130> 13369-WO-PCT <150> IN 201911053553 <151> 2019-12-23 <160> 6 <170> PatentIn Version 3.5 <210> 1 <211> 2256 <212> DNA <213> Homo sapiens <400> 1 atggccaagg agaggggcct aataagcccc agtgattttg cccagctgca aaaatacatg 60 gaatactcca ccaaaaaggt cagtgatgtc ctaaagctct tcgaggatgg cgagatggct 120 aaatatgtcc aaggagatgc cattgggtac gagggattcc agcaattcct gaaaatctat 180 ctcgaagtgg ataatgttcc cagacaccta agcctggcac tgtttcaatc ctttgagact 240 ggtcactgct taaatgagac aaatgtgaca aaagatgtgg tgtgtctcaa tgatgtttcc 300 tgctactttt cccttctgga gggtggtcgg ccagaagaca agttagaatt caccttcaag 360 ctgtacgaca cggacagaaa tgggatcctg gacagctcag aagtggacaa aattatccta 420 cagatgatgc gagtggctga atacctggat tgggatgtgt ctgagctgag gccgattctt 480 caggagatga tgaaagagat tgactatgat ggcagtggct ctgtctctca agctgagtgg 540 gtccgggctg gggccaccac cgtgccactg ctagtgctgc tgggtctgga gatgactctg 600 aaggacgacg gacagcacat gtggaggccc aagaggttcc ccagaccagt ctactgcaat 660 ctgtgcgagt caagcattgg tcttggcaaa cagggactga gctgtaacct ctgtaagtac 720 actgttcacg accagtgtgc catgaaagcc ctgccttgtg aagtcagcac ctatgccaag 780 tctcggaagg acattggtgt ccaatcacat gtgtgggtgc gaggaggctg tgagtccggg 840 cgctgcgacc gctgtcagaa aaagatccgg atctaccaca gtctgaccgg gctgcattgt 900 gtatggtgcc acctagagat ccacgatgac tgcctgcaag cggtgggcca tgagtgtgac 960 tgtgggctgc tccgggatca catcctgcct ccatcttcca tctatcccag tgtcctggcc 1020 tctggaccgg atcgtaaaaa tagcaaaaca agccagaaga ccatggatga tttaaatttg 1080 agcacctctg aggctctgcg gattgaccct gttcctaaca cccacccact tctcgtcttt 1140 gtcaatccta agagtggcgg gaagcagggg cagagggtgc tctggaagtt ccagtatata 1200 ttaaaccctc gacaggtgtt caacctccta aggatggtc ctgagatagg gctccgatta 1260 ttcaaggatg ttcctgatag ccggattttg gtgtgtggtg gagacggcac agtaggctgg 1320 attctagaga ccattgacaa agctaacttg ccagttttgc ctcctgttgc tgtgttgccc 1380 ctgggtactg gaaatgatct ggctcgatgc ctaagatggg gaggaggtta tgaaggacag 1440 aatctggcaa agatcctcaa ggatttagag atgagtaaag tggtacatat ggatcgatgg 1500 tctgtggagg tgatacctca acaaactgaa gaaaaaagtg acccagtccc ctttcaaatc 1560 atcaataact acttctctat tggcgtggat gcctctattg ctcatcgatt ccacatcatg 1620 cgagagaaat atccggagaa gttcaacagc agaatgaaga acaagctatg gtacttcgaa 1680 tttgccacat ctgaatccat cttctcaaca tgcaaaaagc tggagagtc tttgacagtt 1740 gagatctgtg ggaaaccgct ggatctgagc aacctgtccc tagaaggcat cgcagtgcta 1800 aacatcccta gcatgcatgg tggctccaac ctctggggtg ataccaggag accccacatggg 1860 gatatctatg ggatcaacca ggccttaggt gctacagcta aagtcatcac cgaccctgat 1920 atcctgaaaa cctgtgtacc agacctaagt gandagagac tggagtggt tgggctggag 1980 ggtgcaattg agatgggcca aatctatacc aagctcaaga atgctggacg tcggctggcc 2040 aagtgctctg agatcacctt ccaccaca aaaacccttc ccatgcaat tgacggagaa 2100 ccctggatgc agacgccctg tacaatcaag atcaccaca agaaccagat gcccatgctc 2160 atgggcccac cccccgctc caccaatttc tttggctct tgagcggatc ctcggagaca 2220 gtgcggtttc agggacacca ccaccacac cactga 2256 <210> 2 <211> 737 <212> PRT <213> Humans (Homo sapiens) <400> 2 Met Ala Ser Pro Ser Asp Phe Ala Gln Leu Gln Lys Tyr Met Glu Tyr 1 5 10 15 Thr Lys Lys Val Ser Asp Val Leu Lys Leu Phe Glu Asp Gly Glu 20 25 30 Met Ala Lys Tyr Val Gln Gly Asp Ala Ile Gly Tyr Glu Gly Phe Gln 35 40 45 Gln Phe Leu Lys Ile Tyr Leu Glu Val Asp Val Pro Arg His Leu 50 55 60 Ser Leu Ala Leu Phe Gln Ser Phe Glu Thr Gly His Cys Leu Asn Glu 65 70 75 80 Thr Asn Val Thr Lys Asp Val Val Cys Leu Asn Asp Val Ser Cys Tyr 85 90 95 Phe Ser Leu Leu Glu Gly Gly Arg Pro Glu Asp Lys Leu Glu Phe Thr 100 105 110 Phe Lys Leu Tyr Asp Thr Asp Arg Asn Gly Ile Leu Asp Ser Ser Glu 115 120 125 Val Asp Lys Ile Ile Leu Gln Met Met Arg Val Ala Glu Tyr Leu Asp 130 135 140 Trp Asp Val Ser Glu Leu Arg Pro Ile Leu Gln Glu Met Met Lys Glu 145 150 155 160 Ile Asp Tyr Asp Gly Ser Gly Ser Val Ser Gln Ala Glu Trp Val Arg 165 170 175 Ala Gly Ala Thr Thr Val Pro Leu Leu Val Leu Leu Gly Leu Glu Met 180 185 190 Thr Leu Lys Asp Asp Gly Gln His Met Trp Arg Pro Lys Arg Phe Pro 195 200 205 Arg Pro Val Tyr Cys Asn Leu Cys Glu Ser Ser Ile Gly Leu Gly Lys 210 215 220 Gln Gly Leu Ser Cys Asn Leu Cys Lys Tyr Thr Val His Asp Gln Cys 225 230 235 240 Ala Met Lys Ala Leu Pro Cys Glu Val Ser Thr Tyr Ala Lys Ser Arg 245 250 255 Lys Asp Ile Gly Val Gln Ser His Val Trp Val Arg Gly Gly Cys Glu 260 265 270 Ser Gly Arg Cys Asp Arg Cys Gln Lys Lys Ile Arg Ile Tyr His Ser 275 280 285 Leu Thr Gly Leu His Cys Val Trp Cys His Leu Glu Ile His Asp Asp 290 295 300 Cys Leu Gln Ala Val Gly His Glu Cys Asp Cys Gly Leu Leu Arg Asp 305 310 315 320 His Ile Leu Pro Pro Ser Ser Ile Tyr Pro Ser Val Leu Ala Ser Gly 325 330 335 Pro Asp Arg Lys Asn Ser Lys Thr Ser Gln Lys Thr Met Asp Asp Leu 340 345 350 Asn Leu Ser Thr Ser Glu Ala Leu Arg Ile Asp Pro Val Pro Asn Thr 355 360 365 His Pro Leu Leu Val Phe Val Asn Pro Lys Ser Gly Gly Lys Gln Gly 370 375 380 Gln Arg Val Leu Trp Lys Phe Gln Tyr Ile Leu Asn Pro Arg Gln Val 385 390 395 400 Phe Asn Leu Leu Lys Asp Gly Pro Glu Ile Gly Leu Arg Leu Phe Lys 405 410 415 Asp Val Pro Asp Ser Arg Ile Leu Val Cys Gly Gly Asp Gly Thr Val 420 425 430 Gly Trp Ile Leu Glu Thr Ile Asp Lys Ala Asn Leu Pro Val Leu Pro 435 440 445 Pro Val Ala Val Leu Pro Leu Gly Thr Gly Asn Asp Leu Ala Arg Cys 450 455 460 Leu Arg Trp Gly Gly Gly Tyr Glu Gly Gln Asn Leu Ala Lys Ile Leu 465 470 475 480 Lys Asp Leu Glu Met Ser Lys Val Val His Met Asp Arg Trp Ser Val 485 490 495 Glu Val Ile Pro Gln Gln Thr Glu Glu Lys Ser Asp Pro Val Pro Phe 500 505 510 Gln Ile Ile Asn Asn Tyr Phe Ser Ile Gly Val Asp Ala Ser Ile Ala 515 520 525 His Arg Phe His Ile Met Arg Glu Lys Tyr Pro Glu Lys Phe Asn Ser 530 535 540 Arg Met Lys Asn Lys Leu Trp Tyr Phe Glu Phe Ala Thr Ser Glu Ser 545 550 555 560 Ile Phe Ser Thr Cys Lys Lys Leu Glu Glu Ser Leu Thr Val Glu Ile 565 570 575 Cys Gly Lys Pro Leu Asp Leu Ser Asn Leu Ser Leu Glu Gly Ile Ala 580 585 590 Val Leu Asn Ile Pro Ser Met His Gly Gly Ser Asn Leu Trp Gly Asp 595 600 605 Thr Arg Arg Pro His Gly Asp Ile Tyr Gly Ile Asn Gln Ala Leu Gly 610 615 620 Ala Thr Ala Lys Val Ile Thr Asp Pro Asp Ile Leu Lys Thr Cys Val 625 630 635 640 Pro Asp Leu Ser Asp Lys Arg Leu Glu Val Val Gly Leu Glu Gly Ala 645 650 655 Ile Glu Met Gly Gln Ile Tyr Thr Lys Leu Lys Asn Ala Gly Arg Arg 660 665 670 Leu Ala Lys Cys Ser Glu Ile Thr Phe His Thr Thr Lys Thr Leu Pro 675 680 685 Met Gln Ile Asp Gly Glu Pro Trp Met Gln Thr Pro Cys Thr Ile Lys 690 695 700 Ile Thr His Lys Asn Gln Met Pro Met Leu Met Gly Pro Pro Pro Arg 705 710 715 720 Ser Gly Ser Ser Glu Thr Val Arg Phe Gln Gly His His His His His 725 730 735 His <210> 3 <211> 2838 <212> PRT <213> Homo sapiens <400> 3 Ala Thr Gly Gly Ala Gly Cys Cys Gly Cys Gly Gly Gly Ala Cys Gly 1 5 10 15 Gly Thr Ala Gly Cys Cys Cys Cys Gly Ala Gly Gly Cys Cys Cys Gly 20 25 30 Gly Ala Gly Cys Ala Gly Cys Gly Ala Cys Thr Cys Cys Gly Ala Gly 35 40 45 Thr Cys Gly Gly Cys Thr Thr Cys Cys Gly Cys Cys Thr Cys Gly Thr 50 55 60 Cys Cys Ala Gly Cys Gly Gly Cys Thr Cys Cys Gly Ala Gly Cys Gly 65 70 75 80 Cys Gly Ala Cys Gly Cys Cys Gly Gly Thr Cys Cys Cys Gly Ala Gly 85 90 95 Cys Cys Gly Gly Ala Cys Ala Ala Gly Gly Cys Gly Cys Cys Gly Cys 100 105 110 Gly Gly Cys Gly Ala Cys Thr Cys Ala Ala Cys Ala Ala Gly Cys Gly 115 120 125 Gly Cys Gly Cys Thr Thr Cys Cys Cys Gly Gly Gly Gly Cys Thr Gly 130 135 140 Cys Gly Gly Cys Thr Cys Thr Thr Cys Gly Gly Gly Cys Ala Cys Ala 145 150 155 160 Gly Gly Ala Ala Ala Gly Cys Cys Ala Thr Cys Ala Cys Gly Ala Ala 165 170 175 Gly Thr Cys Gly Gly Gly Cys Cys Thr Cys Cys Ala Gly Cys Ala Cys 180 185 190 Cys Thr Gly Gly Cys Cys Cys Cys Cys Cys Cys Thr Cys Cys Gly Cys 195 200 205 Cys Cys Ala Cys Cys Cys Cys Thr Gly Gly Gly Gly Cys Cys Cys Cys 210 215 220 Gly Thr Gly Cys Ala Gly Cys Gly Ala Gly Thr Cys Ala Gly Ala Gly 225 230 235 240 Cys Gly Gly Cys Ala Gly Ala Thr Cys Cys Gly Gly Ala Gly Thr Ala 245 250 255 Cys Ala Gly Thr Gly Gly Ala Cys Thr Gly Gly Ala Gly Cys Gly Ala 260 265 270 Gly Thr Cys Ala Gly Cys Gly Ala Cys Ala Thr Ala Thr Gly Gly Gly 275 280 285 Gly Ala Gly Cys Ala Cys Ala Thr Cys Thr Gly Gly Thr Thr Cys Gly 290 295 300 Ala Gly Ala Cys Cys Ala Ala Cys Gly Thr Gly Thr Cys Cys Gly Gly 305 310 315 320 Gly Gly Ala Cys Thr Thr Cys Thr Gly Cys Thr Ala Cys Gly Thr Thr 325 330 335 Gly Gly Gly Gly Ala Gly Cys Ala Gly Thr Ala Cys Thr Gly Thr Gly 340 345 350 Thr Ala Gly Cys Cys Ala Gly Gly Ala Thr Gly Cys Thr Gly Cys Ala 355 360 365 Gly Ala Ala Gly Thr Cys Ala Gly Thr Gly Thr Cys Thr Cys Gly Ala 370 375 380 Ala Gly Ala Ala Ala Gly Thr Gly Cys Gly Cys Ala Gly Cys Cys Thr 385 390 395 400 Gly Cys Ala Ala Gly Ala Thr Thr Gly Thr Gly Gly Thr Gly Cys Ala 405 410 415 Cys Ala Cys Gly Cys Cys Cys Thr Gly Cys Ala Thr Cys Gly Ala Gly 420 425 430 Cys Ala Gly Cys Thr Gly Gly Ala Gly Ala Ala Gly Ala Thr Ala Ala 435 440 445 Ala Thr Thr Thr Cys Cys Gly Cys Thr Gly Thr Ala Ala Gly Cys Cys 450 455 460 Gly Thr Cys Cys Thr Thr Cys Cys Gly Thr Gly Ala Ala Thr Cys Ala 465 470 475 480 Gly Gly Cys Thr Cys Cys Ala Gly Gly Ala Ala Thr Gly Thr Cys Cys 485 490 495 Gly Cys Gly Ala Gly Cys Cys Ala Ala Cys Cys Thr Thr Thr Gly Thr 500 505 510 Ala Cys Gly Gly Cys Ala Cys Cys Ala Cys Thr Gly Gly Gly Thr Ala 515 520 525 Cys Ala Cys Ala Gly Ala Cys Gly Ala Cys Gly Cys Cys Ala Gly Gly 530 535 540 Ala Cys Gly Gly Cys Ala Ala Gly Thr Gly Thr Cys Gly Gly Cys Ala 545 550 555 560 Cys Thr Gly Thr Gly Gly Gly Ala Ala Gly Gly Gly Ala Thr Thr Cys 565 570 575 Cys Ala Gly Cys Ala Gly Ala Ala Gly Thr Thr Cys Ala Cys Cys Thr 580 585 590 Thr Cys Cys Ala Cys Ala Gly Cys Ala Ala Gly Gly Ala Gly Ala Thr 595 600 605 Thr Gly Thr Gly Gly Cys Cys Ala Thr Cys Ala Gly Cys Thr Gly Cys 610 615 620 Thr Cys Gly Thr Gly Gly Thr Gly Cys Ala Ala Gly Cys Ala Gly Gly 625 630 635 640 Cys Ala Thr Ala Cys Cys Ala Cys Ala Gly Cys Ala Ala Gly Gly Thr 645 650 655 Gly Thr Cys Cys Thr Gly Cys Thr Thr Cys Ala Thr Gly Cys Thr Gly 660 665 670 Cys Ala Gly Cys Ala Gly Ala Thr Cys Gly Ala Gly Gly Ala Gly Cys 675 680 685 Cys Gly Thr Gly Cys Thr Cys Gly Cys Thr Gly Gly Gly Gly Gly Thr 690 695 700 Cys Cys Ala Cys Gly Cys Ala Gly Cys Cys Gly Thr Gly Gly Thr Cys 705 710 715 720 Ala Thr Cys Cys Cys Gly Cys Cys Cys Ala Cys Cys Thr Gly Gly Ala 725 730 735 Thr Cys Cys Thr Cys Cys Gly Cys Gly Cys Cys Cys Gly Gly Ala Gly 740 745 750 Gly Cys Cys Cys Cys Ala Gly Ala Ala Thr Ala Cys Thr Cys Thr Gly 755 760 765 Ala Ala Ala Gly Cys Ala Ala Gly Cys Ala Ala Gly Ala Ala Gly Ala 770 775 780 Ala Gly Ala Ala Gly Ala Gly Gly Gly Cys Ala Thr Cys Cys Thr Thr 785 790 795 800 Cys Ala Ala Gly Ala Gly Gly Ala Ala Gly Thr Cys Cys Ala Gly Cys 805 810 815 Ala Ala Gly Ala Ala Ala Gly Gly Gly Cys Cys Thr Gly Ala Gly Gly 820 825 830 Ala Gly Gly Gly Cys Cys Gly Cys Thr Gly Gly Ala Gly Ala Cys Cys 835 840 845 Cys Thr Thr Cys Ala Thr Cys Ala Thr Cys Ala Gly Gly Cys Cys Cys 850 855 860 Ala Cys Cys Cys Cys Cys Thr Cys Cys Cys Cys Gly Cys Thr Cys Ala 865 870 875 880 Thr Gly Ala Ala Gly Cys Cys Cys Cys Thr Gly Cys Thr Gly Gly Thr 885 890 895 Gly Thr Thr Thr Gly Thr Gly Ala Ala Cys Cys Cys Cys Ala Ala Gly 900 905 910 Ala Gly Thr Gly Gly Gly Gly Gly Cys Ala Ala Cys Cys Ala Gly Gly 915 920 925 Gly Thr Gly Cys Ala Ala Ala Gly Ala Thr Cys Ala Thr Cys Cys Ala 930 935 940 Gly Thr Cys Thr Thr Thr Cys Cys Thr Cys Thr Gly Gly Thr Ala Thr 945 950 955 960 Cys Thr Cys Ala Ala Thr Cys Cys Cys Cys Gly Ala Cys Ala Ala Gly 965 970 975 Thr Cys Thr Thr Cys Gly Ala Cys Cys Thr Gly Ala Gly Cys Cys Ala 980 985 990 Gly Gly Gly Ala Gly Gly Gly Cys Cys Cys Ala Ala Gly Gly Ala Gly 995 1000 1005 Gly Cys Gly Cys Thr Gly Gly Ala Gly Ala Thr Gly Thr Ala Cys 1010 1015 1020 Cys Gly Cys Ala Ala Ala Gly Thr Gly Cys Ala Cys Ala Ala Cys 1025 1030 1035 Cys Thr Gly Cys Gly Gly Ala Thr Cys Cys Thr Gly Gly Cys Gly 1040 1045 1050 Thr Gly Cys Gly Gly Gly Gly Gly Cys Gly Ala Cys Gly Gly Cys 1055 1060 1065 Ala Cys Gly Gly Thr Gly Gly Gly Cys Thr Gly Gly Ala Thr Cys 1070 1075 1080 Cys Thr Cys Thr Cys Cys Ala Cys Cys Cys Thr Gly Gly Ala Cys 1085 1090 1095 Cys Ala Gly Cys Thr Ala Cys Gly Cys Cys Thr Gly Ala Ala Gly 1100 1105 1110 Cys Cys Gly Cys Cys Ala Cys Cys Cys Cys Cys Thr Gly Thr Thr 1115 1120 1125 Gly Cys Cys Ala Thr Cys Cys Thr Gly Cys Cys Cys Cys Thr Gly 1130 1135 1140 Gly Gly Thr Ala Cys Thr Gly Gly Cys Ala Ala Cys Gly Ala Cys 1145 1150 1155 Thr Thr Gly Gly Cys Cys Cys Gly Ala Ala Cys Cys Cys Thr Cys 1160 1165 1170 Ala Ala Cys Thr Gly Gly Gly Gly Thr Gly Gly Gly Gly Gly Cys 1175 1180 1185 Thr Ala Cys Ala Cys Ala Gly Ala Thr Gly Ala Gly Cys Cys Thr 1190 1195 1200 Gly Thr Gly Thr Cys Cys Ala Ala Gly Ala Thr Cys Cys Thr Cys 1205 1210 1215 Thr Cys Cys Cys Ala Cys Gly Thr Gly Gly Ala Gly Gly Ala Gly 1220 1225 1230 Gly Gly Gly Ala Ala Cys Gly Thr Gly Gly Thr Ala Cys Ala Gly 1235 1240 1245 Cys Thr Gly Gly Ala Cys Cys Gly Cys Thr Gly Gly Gly Ala Cys 1250 1255 1260 Cys Thr Cys Cys Ala Cys Gly Cys Thr Gly Ala Gly Cys Cys Cys 1265 1270 1275 Ala Ala Cys Cys Cys Cys Gly Ala Gly Gly Cys Ala Gly Gly Gly 1280 1285 1290 Cys Cys Thr Gly Ala Gly Gly Ala Cys Cys Gly Ala Gly Ala Thr 1295 1300 1305 Gly Ala Ala Gly Gly Cys Gly Cys Cys Ala Cys Cys Gly Ala Cys 1310 1315 1320 Cys Gly Gly Thr Thr Gly Cys Cys Cys Cys Thr Gly Gly Ala Thr 1325 1330 1335 Gly Thr Cys Thr Thr Cys Ala Ala Cys Ala Ala Cys Thr Ala Cys 1340 1345 1350 Thr Thr Cys Ala Gly Cys Cys Thr Gly Gly Gly Cys Thr Thr Thr 1355 1360 1365 Gly Ala Cys Gly Cys Cys Cys Ala Cys Gly Thr Cys Ala Cys Cys 1370 1375 1380 Cys Thr Gly Gly Ala Gly Thr Thr Cys Cys Ala Cys Gly Ala Gly 1385 1390 1395 Thr Cys Thr Cys Gly Ala Gly Ala Gly Gly Cys Cys Ala Ala Cys 1400 1405 1410 Cys Cys Ala Gly Ala Gly Ala Ala Ala Thr Thr Cys Ala Ala Cys 1415 1420 1425 Ala Gly Cys Cys Gly Cys Thr Thr Thr Cys Gly Gly Ala Ala Thr 1430 1435 1440 Ala Ala Gly Ala Thr Gly Thr Thr Cys Thr Ala Cys Gly Cys Cys 1445 1450 1455 Gly Gly Gly Ala Cys Ala Gly Cys Thr Thr Thr Cys Thr Cys Thr 1460 1465 1470 Gly Ala Cys Thr Thr Cys Cys Thr Gly Ala Thr Gly Gly Gly Cys 1475 1480 1485 Ala Gly Cys Thr Cys Cys Ala Ala Gly Gly Ala Cys Cys Thr Gly 1490 1495 1500 Gly Cys Cys Ala Ala Gly Cys Ala Cys Ala Thr Cys Cys Gly Ala 1505 1510 1515 Gly Thr Gly Gly Thr Gly Thr Gly Thr Gly Ala Thr Gly Gly Ala 1520 1525 1530 Ala Thr Gly Gly Ala Cys Thr Thr Gly Ala Cys Thr Cys Cys Cys 1535 1540 1545 Ala Ala Gly Ala Thr Cys Cys Ala Gly Gly Ala Cys Cys Thr Gly 1550 1555 1560 Ala Ala Ala Cys Cys Cys Cys Ala Gly Thr Gly Thr Gly Thr Thr 1565 1570 1575 Gly Thr Thr Thr Thr Cys Cys Thr Gly Ala Ala Cys Ala Thr Cys 1580 1585 1590 Cys Cys Cys Ala Gly Gly Thr Ala Cys Thr Gly Thr Gly Cys Gly 1595 1600 1605 Gly Gly Cys Ala Cys Cys Ala Thr Gly Cys Cys Cys Thr Gly Gly 1610 1615 1620 Gly Gly Cys Cys Ala Cys Cys Cys Thr Gly Gly Gly Gly Ala Gly 1625 1630 1635 Cys Ala Cys Cys Ala Cys Gly Ala Cys Thr Thr Thr Gly Ala Gly 1640 1645 1650 Cys Cys Cys Cys Ala Gly Cys Gly Gly Cys Ala Thr Gly Ala Cys 1655 1660 1665 Gly Ala Cys Gly Gly Cys Thr Ala Cys Cys Thr Cys Gly Ala Gly 1670 1675 1680 Gly Thr Cys Ala Thr Thr Gly Gly Cys Thr Thr Cys Ala Cys Cys 1685 1690 1695 Ala Thr Gly Ala Cys Gly Thr Cys Gly Thr Thr Gly Gly Cys Cys 1700 1705 1710 Gly Cys Gly Cys Thr Gly Cys Ala Gly Gly Thr Gly Gly Gly Cys 1715 1720 1725 Gly Gly Ala Cys Ala Cys Gly Gly Cys Gly Ala Gly Cys Gly Gly 1730 1735 1740 Cys Thr Gly Ala Cys Gly Cys Ala Gly Thr Gly Thr Cys Gly Cys 1745 1750 1755 Gly Ala Gly Gly Thr Gly Gly Thr Gly Cys Thr Cys Ala Cys Cys 1760 1765 1770 Ala Cys Ala Thr Cys Cys Ala Ala Gly Gly Cys Cys Ala Thr Cys 1775 1780 1785 Cys Cys Gly Gly Thr Gly Cys Ala Gly Gly Thr Gly Gly Ala Thr 1790 1795 1800 Gly Gly Cys Gly Ala Gly Cys Cys Cys Thr Gly Cys Ala Ala Gly 1805 1810 1815 Cys Thr Thr Gly Cys Ala Gly Cys Cys Thr Cys Ala Cys Gly Cys 1820 1825 1830 Ala Thr Cys Cys Gly Cys Ala Thr Cys Gly Cys Cys Cys Thr Gly 1835 1840 1845 Cys Gly Cys Ala Ala Cys Cys Ala Gly Gly Cys Cys Ala Cys Cys 1850 1855 1860 Ala Thr Gly Gly Thr Gly Cys Ala Gly Ala Ala Gly Gly Cys Cys 1865 1870 1875 Ala Ala Gly Cys Gly Gly Cys Gly Gly Ala Gly Cys Gly Cys Cys 1880 1885 1890 Gly Cys Cys Cys Cys Cys Cys Thr Gly Cys Ala Cys Ala Gly Cys 1895 1900 1905 Gly Ala Cys Cys Ala Gly Cys Ala Gly Cys Cys Gly Gly Thr Gly 1910 1915 1920 Cys Cys Ala Gly Ala Gly Cys Ala Gly Thr Thr Gly Cys Gly Cys 1925 1930 1935 Ala Thr Cys Cys Ala Gly Gly Thr Gly Ala Gly Thr Cys Gly Cys 1940 1945 1950 Gly Thr Cys Ala Gly Cys Ala Thr Gly Cys Ala Cys Gly Ala Cys 1955 1960 1965 Thr Ala Thr Gly Ala Gly Gly Cys Cys Cys Thr Gly Cys Ala Cys 1970 1975 1980 Thr Ala Cys Gly Ala Cys Ala Ala Gly Gly Ala Gly Cys Ala Gly 1985 1990 1995 Cys Thr Cys Ala Ala Gly Gly Ala Gly Gly Cys Cys Thr Cys Thr 2000 2005 2010 Gly Thr Gly Cys Cys Gly Cys Thr Gly Gly Gly Cys Ala Cys Thr 2015 2020 2025 Gly Thr Gly Gly Thr Gly Gly Thr Cys Cys Cys Ala Gly Gly Ala 2030 2035 2040 Gly Ala Cys Ala Gly Thr Gly Ala Cys Cys Thr Ala Gly Ala Gly 2045 2050 2055 Cys Thr Cys Thr Gly Cys Cys Gly Thr Gly Cys Cys Cys Ala Cys 2060 2065 2070 Ala Thr Thr Gly Ala Gly Ala Gly Ala Cys Thr Cys Cys Ala Gly 2075 2080 2085 Cys Ala Gly Gly Ala Gly Cys Cys Cys Gly Ala Thr Gly Gly Thr 2090 2095 2100 Gly Cys Thr Gly Gly Ala Gly Cys Cys Ala Ala Gly Thr Cys Cys 2105 2110 2115 Cys Cys Gly Ala Cys Ala Thr Gly Cys Cys Ala Gly Ala Ala Ala 2120 2125 2130 Cys Thr Gly Thr Cys Cys Cys Cys Cys Ala Ala Gly Thr Gly Gly 2135 2140 2145 Thr Gly Cys Thr Thr Cys Cys Thr Gly Gly Ala Cys Gly Cys Cys 2150 2155 2160 Ala Cys Cys Ala Cys Thr Gly Cys Cys Ala Gly Cys Cys Gly Cys 2165 2170 2175 Thr Thr Cys Thr Ala Cys Ala Gly Gly Ala Thr Cys Gly Ala Cys 2180 2185 2190 Cys Gly Ala Gly Cys Cys Cys Ala Gly Gly Ala Gly Cys Ala Cys 2195 2200 2205 Cys Thr Cys Ala Ala Cys Thr Ala Thr Gly Thr Gly Ala Cys Thr 2210 2215 2220 Gly Ala Gly Ala Thr Cys Gly Cys Ala Cys Ala Gly Gly Ala Thr 2225 2230 2235 Gly Ala Gly Ala Thr Thr Thr Ala Thr Ala Thr Cys Cys Thr Gly 2240 2245 2250 Gly Ala Cys Cys Cys Thr Gly Ala Gly Cys Thr Gly Cys Thr Gly 2255 2260 2265 Gly Gly Gly Gly Cys Ala Thr Cys Gly Gly Cys Cys Cys Gly Gly 2270 2275 2280 Cys Cys Thr Gly Ala Cys Cys Thr Cys Cys Cys Ala Ala Cys Cys 2285 2290 2295 Cys Cys Cys Ala Cys Thr Thr Cys Cys Cys Cys Thr Cys Thr Cys 2300 2305 2310 Cys Cys Cys Ala Cys Cys Thr Cys Ala Cys Cys Cys Thr Gly Cys 2315 2320 2325 Thr Cys Ala Cys Cys Cys Ala Cys Gly Cys Cys Cys Cys Gly Gly 2330 2335 2340 Thr Cys Ala Cys Thr Gly Cys Ala Ala Gly Gly Gly Gly Ala Thr 2345 2350 2355 Gly Cys Thr Gly Cys Ala Cys Cys Cys Cys Cys Thr Cys Ala Ala 2360 2365 2370 Gly Gly Thr Gly Ala Ala Gly Ala Gly Cys Thr Gly Ala Thr Thr 2375 2380 2385 Gly Ala Gly Gly Cys Thr Gly Cys Cys Ala Ala Gly Ala Gly Gly 2390 2395 2400 Ala Ala Cys Gly Ala Cys Thr Thr Cys Thr Gly Thr Ala Ala Gly 2405 2410 2415 Cys Thr Cys Cys Ala Gly Gly Ala Gly Cys Thr Gly Cys Ala Cys 2420 2425 2430 Cys Gly Ala Gly Cys Thr Gly Gly Gly Gly Gly Cys Gly Ala Cys 2435 2440 2445 Cys Thr Cys Ala Thr Gly Cys Ala Cys Cys Gly Ala Gly Ala Cys 2450 2455 2460 Gly Ala Gly Cys Ala Gly Ala Gly Thr Cys Gly Cys Ala Cys Gly 2465 2470 2475 Cys Thr Cys Cys Thr Gly Cys Ala Cys Cys Ala Cys Gly Cys Ala 2480 2485 2490 Gly Thr Cys Ala Gly Cys Ala Cys Thr Gly Gly Cys Ala Gly Cys 2495 2500 2505 Ala Ala Gly Gly Ala Thr Gly Thr Gly Gly Thr Cys Cys Gly Cys 2510 2515 2520 Thr Ala Cys Cys Thr Gly Cys Thr Gly Gly Ala Cys Cys Ala Cys 2525 2530 2535 Gly Cys Cys Cys Cys Cys Cys Cys Ala Gly Ala Gly Ala Thr Cys 2540 2545 2550 Cys Thr Thr Gly Ala Thr Gly Cys Gly Gly Thr Gly Gly Ala Gly 2555 2560 2565 Gly Ala Ala Ala Ala Cys Gly Gly Gly Gly Ala Gly Ala Cys Cys 2570 2575 2580 Thr Gly Thr Thr Thr Gly Cys Ala Cys Cys Ala Ala Gly Cys Ala 2585 2590 2595 Gly Cys Gly Gly Cys Cys Cys Thr Gly Gly Gly Cys Cys Ala Gly 2600 2605 2610 Cys Gly Cys Ala Cys Cys Ala Thr Cys Thr Gly Cys Cys Ala Cys 2615 2620 2625 Thr Ala Cys Ala Thr Cys Gly Thr Gly Gly Ala Gly Gly Cys Cys 2630 2635 2640 Gly Gly Gly Gly Cys Cys Thr Cys Gly Cys Thr Cys Ala Thr Gly 2645 2650 2655 Ala Ala Gly Ala Cys Ala Gly Ala Cys Cys Ala Gly Cys Ala Gly 2660 2665 2670 Gly Gly Cys Gly Ala Cys Ala Cys Thr Cys Cys Cys Cys Gly Gly 2675 2680 2685 Cys Ala Gly Cys Gly Gly Gly Cys Thr Gly Ala Gly Ala Ala Gly 2690 2695 2700 Gly Cys Thr Cys Ala Gly Gly Ala Cys Ala Cys Cys Gly Ala Gly 2705 2710 2715 Cys Thr Gly Gly Cys Cys Gly Cys Cys Thr Ala Cys Cys Thr Gly 2720 2725 2730 Gly Ala Gly Ala Ala Cys Cys Gly Gly Cys Ala Gly Cys Ala Cys 2735 2740 2745 Thr Ala Cys Cys Ala Gly Ala Thr Gly Ala Thr Cys Cys Ala Gly 2750 2755 2760 Cys Gly Gly Gly Ala Gly Gly Ala Cys Cys Ala Gly Gly Ala Gly 2765 2770 2775 Ala Cys Gly Gly Cys Thr Gly Thr Gly Gly Gly Ala Thr Cys Cys 2780 2785 2790 Thr Cys Gly Gly Ala Gly Ala Cys Ala Gly Thr Gly Cys Gly Gly 2795 2800 2805 Thr Thr Thr Cys Ala Gly Gly Gly Ala Cys Ala Cys Cys Ala Cys 2810 2815 2820 Cys Ala Cys Cys Ala Thr Cys Ala Cys Cys Ala Cys Thr Gly Ala 2825 2830 2835 <210> 4 <211> 945 <212> PRT <213> Homo sapiens <400> 4 Met Glu Pro Arg Asp Gly Ser Pro Glu Ala Arg Ser Ser Asp Ser Glu 1 5 10 15 Ser Ala Ser Ala Ser Ser Ser Gly Ser Glu Arg Asp Ala Gly Pro Glu 20 25 30 Pro Asp Lys Ala Pro Arg Arg Leu Asn Lys Arg Arg Phe Pro Gly Leu 35 40 45 Arg Leu Phe Gly His Arg Lys Ala Ile Thr Lys Ser Gly Leu Gln His 50 55 60 Leu Ala Pro Pro Pro Pro Thr Pro Gly Ala Pro Cys Ser Glu Ser Glu 65 70 75 80 Arg Gln Ile Arg Ser Thr Val Asp Trp Ser Glu Ser Ala Thr Tyr Gly 85 90 95 Glu His Ile Trp Phe Glu Thr Asn Val Ser Gly Asp Phe Cys Tyr Val 100 105 110 Gly Glu Gln Tyr Cys Val Ala Arg Met Leu Gln Lys Ser Val Ser Arg 115 120 125 Arg Lys Cys Ala Ala Cys Lys Ile Val Val His Thr Pro Cys Ile Glu 130 135 140 Gln Leu Glu Lys Ile Asn Phe Arg Cys Lys Pro Ser Phe Arg Glu Ser 145 150 155 160 Gly Ser Arg Asn Val Arg Glu Pro Thr Phe Val Arg His His Trp Val 165 170 175 His Arg Arg Arg Gln Asp Gly Lys Cys Arg His Cys Gly Lys Gly Phe 180 185 190 Gln Gln Lys Phe Thr Phe His Ser Lys Glu Ile Val Ala Ile Ser Cys 195 200 205 Ser Trp Cys Lys Gln Ala Tyr His Ser Lys Val Ser Cys Phe Met Leu 210 215 220 Gln Gln Ile Glu Glu Pro Cys Ser Leu Gly Val His Ala Ala Val Val 225 230 235 240 Ile Pro Pro Thr Trp Ile Leu Arg Ala Arg Arg Pro Gln Asn Thr Leu 245 250 255 Lys Ala Ser Lys Lys Lys Lys Arg Ala Ser Phe Lys Arg Lys Ser Ser 260 265 270 Lys Lys Gly Pro Glu Glu Gly Arg Trp Arg Pro Phe Ile Ile Arg Pro 275 280 285 Thr Pro Ser Pro Leu Met Lys Pro Leu Leu Val Phe Val Asn Pro Lys 290 295 300 Ser Gly Gly Asn Gln Gly Ala Lys Ile Ile Gln Ser Phe Leu Trp Tyr 305 310 315 320 Leu Asn Pro Arg Gln Val Phe Asp Leu Ser Gln Gly Gly Pro Lys Glu 325 330 335 Ala Leu Glu Met Tyr Arg Lys Val His Asn Leu Arg Ile Leu Ala Cys 340 345 350 Gly Gly Asp Gly Thr Val Gly Trp Ile Leu Ser Thr Leu Asp Gln Leu 355 360 365 Arg Leu Lys Pro Pro Pro Pro Val Ala Ile Leu Pro Leu Gly Thr Gly 370 375 380 Asn Asp Leu Ala Arg Thr Leu Asn Trp Gly Gly Gly Tyr Thr Asp Glu 385 390 395 400 Pro Val Ser Lys Ile Leu Ser His Val Glu Glu Gly Asn Val Val Gln 405 410 415 Leu Asp Arg Trp Asp Leu His Ala Glu Pro Asn Pro Glu Ala Gly Pro 420 425 430 Glu Asp Arg Asp Glu Gly Ala Thr Asp Arg Leu Pro Leu Asp Val Phe 435 440 445 Asn Asn Tyr Phe Ser Leu Gly Phe Asp Ala His Val Thr Leu Glu Phe 450 455 460 His Glu Ser Arg Glu Ala Asn Pro Glu Lys Phe Asn Ser Arg Phe Arg 465 470 475 480 Asn Lys Met Phe Tyr Ala Gly Thr Ala Phe Ser Asp Phe Leu Met Gly 485 490 495 Ser Ser Lys Asp Leu Ala Lys His Ile Arg Val Val Cys Asp Gly Met 500 505 510 Asp Leu Thr Pro Lys Ile Gln Asp Leu Lys Pro Gln Cys Val Val Phe 515 520 525 Leu Asn Ile Pro Arg Tyr Cys Ala Gly Thr Met Pro Trp Gly His Pro 530 535 540 Gly Glu His His Asp Phe Glu Pro Gln Arg His Asp Asp Gly Tyr Leu 545 550 555 560 Glu Val Ile Gly Phe Thr Met Thr Ser Leu Ala Ala Leu Gln Val Gly 565 570 575 Gly His Gly Glu Arg Leu Thr Gln Cys Arg Glu Val Val Leu Thr Thr 580 585 590 Ser Lys Ala Ile Pro Val Gln Val Asp Gly Glu Pro Cys Lys Leu Ala 595 600 605 Ala Ser Arg Ile Arg Ile Ala Leu Arg Asn Gln Ala Thr Met Val Gln 610 615 620 Lys Ala Lys Arg Arg Ser Ala Ala Pro Leu His Ser Asp Gln Gln Pro 625 630 635 640 Val Pro Glu Gln Leu Arg Ile Gln Val Ser Arg Val Ser Met His Asp 645 650 655 Tyr Glu Ala Leu His Tyr Asp Lys Glu Gln Leu Lys Glu Ala Ser Val 660 665 670 Pro Leu Gly Thr Val Val Val Pro Gly Asp Ser Asp Leu Glu Leu Cys 675 680 685 Arg Ala His Ile Glu Arg Leu Gln Gln Glu Pro Asp Gly Ala Gly Ala 690 695 700 Lys Ser Pro Thr Cys Gln Lys Leu Ser Pro Lys Trp Cys Phe Leu Asp 705 710 715 720 Ala Thr Thr Ala Ser Arg Phe Tyr Arg Ile Asp Arg Ala Gln Glu His 725 730 735 Leu Asn Tyr Val Thr Glu Ile Ala Gln Asp Glu Ile Tyr Ile Leu Asp 740 745 750 Pro Glu Leu Leu Gly Ala Ser Ala Arg Pro Asp Leu Pro Thr Pro Thr 755 760 765 Ser Pro Leu Pro Thr Ser Pro Cys Ser Pro Thr Pro Arg Ser Leu Gln 770 775 780 Gly Asp Ala Ala Pro Pro Gln Gly Glu Glu Leu Ile Glu Ala Ala Lys 785 790 795 800 Arg Asn Asp Phe Cys Lys Leu Gln Glu Leu His Arg Ala Gly Gly Asp 805 810 815 Leu Met His Arg Asp Glu Gln Ser Arg Thr Leu Leu His His Ala Val 820 825 830 Ser Thr Gly Ser Lys Asp Val Val Arg Tyr Leu Leu Asp His Ala Pro 835 840 845 Pro Glu Ile Leu Asp Ala Val Glu Glu Asn Gly Glu Thr Cys Leu His 850 855 860 Gln Ala Ala Ala Leu Gly Gln Arg Thr Ile Cys His Tyr Ile Val Glu 865 870 875 880 Ala Gly Ala Ser Leu Met Lys Thr Asp Gln Gln Gly Asp Thr Pro Arg 885 890 895 Gln Arg Ala Glu Lys Ala Gln Asp Thr Glu Leu Ala Ala Tyr Leu Glu 900 905 910 Asn Arg Gln His Tyr Gln Met Ile Gln Arg Glu Asp Gln Glu Thr Ala 915 920 925 Val Gly Ser Ser Glu Thr Val Arg Phe Gln Gly His His His His His 930 935 940 His 945 <210> 5 <211> 2214 <212> PRT <213> Homo sapiens <400> 5 Ala Thr Gly Gly Cys Thr Thr Cys Cys Cys Cys Ala Ala Gly Cys Gly 1 5 10 15 Ala Cys Thr Thr Cys Gly Cys Cys Cys Ala Gly Cys Thr Gly Cys Ala 20 25 30 Gly Ala Ala Gly Thr Ala Cys Ala Thr Gly Gly Ala Ala Thr Ala Cys 35 40 45 Ala Gly Cys Ala Cys Cys Ala Ala Gly Ala Ala Gly Gly Thr Gly Thr 50 55 60 Cys Thr Gly Ala Cys Gly Thr Cys Cys Thr Gly Ala Ala Gly Cys Thr 65 70 75 80 Gly Thr Thr Cys Gly Ala Gly Gly Ala Cys Gly Gly Thr Gly Ala Ala 85 90 95 Ala Thr Gly Gly Cys Thr Ala Ala Gly Thr Ala Cys Gly Thr Cys Cys 100 105 110 Ala Gly Gly Gly Cys Gly Ala Cys Gly Cys Thr Ala Thr Cys Gly Gly 115 120 125 Ala Thr Ala Cys Gly Ala Gly Gly Gly Ala Thr Thr Cys Cys Ala Gly 130 135 140 Cys Ala Gly Thr Thr Cys Cys Thr Gly Ala Ala Gly Ala Thr Cys Thr 145 150 155 160 Ala Cys Cys Thr Gly Gly Ala Ala Gly Thr Gly Gly Ala Cys Ala Ala 165 170 175 Cys Gly Thr Cys Cys Cys Cys Ala Gly Gly Cys Ala Cys Cys Thr Gly 180 185 190 Thr Cys Ala Cys Thr Gly Gly Cys Thr Cys Thr Gly Thr Thr Cys Cys 195 200 205 Ala Gly Thr Cys Cys Thr Thr Cys Gly Ala Gly Ala Cys Thr Gly Gly 210 215 220 Cys Cys Ala Cys Thr Gly Cys Cys Thr Gly Ala Ala Cys Gly Ala Ala 225 230 235 240 Ala Cys Cys Ala Ala Cys Gly Thr Cys Ala Cys Thr Ala Ala Gly Gly 245 250 255 Ala Cys Gly Thr Gly Gly Thr Cys Thr Gly Cys Cys Thr Gly Ala Ala 260 265 270 Cys Gly Ala Cys Gly Thr Gly Ala Gly Cys Thr Gly Cys Thr Ala Cys 275 280 285 Thr Thr Cys Thr Cys Thr Cys Thr Gly Cys Thr Gly Gly Ala Gly Gly 290 295 300 Gly Thr Gly Gly Cys Ala Gly Ala Cys Cys Ala Gly Ala Gly Gly Ala 305 310 315 320 Cys Ala Ala Gly Cys Thr Gly Gly Ala Ala Thr Thr Cys Ala Cys Cys 325 330 335 Thr Thr Cys Ala Ala Gly Cys Thr Gly Thr Ala Cys Gly Ala Cys Ala 340 345 350 Cys Thr Gly Ala Cys Cys Gly Cys Ala Ala Cys Gly Gly Ala Ala Thr 355 360 365 Cys Cys Thr Gly Gly Ala Cys Thr Cys Cys Ala Gly Cys Gly Ala Ala 370 375 380 Gly Thr Gly Gly Ala Cys Ala Ala Gly Ala Thr Cys Ala Thr Cys Cys 385 390 395 400 Thr Gly Cys Ala Gly Ala Thr Gly Ala Thr Gly Cys Gly Thr Gly Thr 405 410 415 Cys Gly Cys Thr Gly Ala Gly Thr Ala Cys Cys Thr Gly Gly Ala Cys 420 425 430 Thr Gly Gly Gly Ala Cys Gly Thr Gly Ala Gly Cys Gly Ala Ala Cys 435 440 445 Thr Gly Ala Gly Gly Cys Cys Thr Ala Thr Cys Cys Thr Gly Cys Ala 450 455 460 Gly Gly Ala Gly Ala Thr Gly Ala Thr Gly Ala Ala Gly Gly Ala Ala 465 470 475 480 Ala Thr Cys Gly Ala Cys Thr Ala Cys Gly Ala Cys Gly Gly Cys Thr 485 490 495 Cys Thr Gly Gly Ala Thr Cys Ala Gly Thr Gly Thr Cys Cys Cys Ala 500 505 510 Gly Gly Cys Thr Gly Ala Gly Thr Gly Gly Gly Thr Cys Cys Gly Cys 515 520 525 Gly Cys Thr Gly Gly Thr Gly Cys Thr Ala Cys Cys Ala Cys Thr Gly 530 535 540 Thr Gly Cys Cys Ala Cys Thr Gly Cys Thr Gly Gly Thr Cys Cys Thr 545 550 555 560 Gly Cys Thr Gly Gly Gly Ala Cys Thr Gly Gly Ala Ala Ala Thr Gly 565 570 575 Ala Cys Cys Cys Thr Gly Ala Ala Gly Gly Ala Cys Gly Ala Cys Gly 580 585 590 Gly Thr Cys Ala Gly Cys Ala Cys Ala Thr Gly Thr Gly Gly Cys Gly 595 600 605 Cys Cys Cys Ala Ala Ala Gly Cys Gly Thr Thr Thr Cys Cys Cys Cys 610 615 620 Ala Gly Gly Cys Cys Ala Gly Thr Cys Thr Ala Cys Thr Gly Cys Ala 625 630 635 640 Ala Cys Cys Thr Gly Thr Gly Cys Gly Ala Gly Thr Cys Thr Thr Cys 645 650 655 Ala Ala Thr Cys Gly Gly Thr Cys Thr Gly Gly Gly Cys Ala Ala Gly 660 665 670 Cys Ala Gly Gly Gly Cys Cys Thr Gly Thr Cys Ala Thr Gly Cys Ala 675 680 685 Ala Cys Cys Thr Gly Thr Gly Cys Ala Ala Gly Thr Ala Cys Ala Cys 690 695 700 Cys Gly Thr Gly Cys Ala Cys Gly Ala Cys Cys Ala Gly Thr Gly Cys 705 710 715 720 Gly Cys Thr Ala Thr Gly Ala Ala Gly Gly Cys Cys Cys Thr Gly Cys 725 730 735 Cys Cys Thr Gly Cys Gly Ala Gly Gly Thr Cys Thr Cys Ala Ala Cys 740 745 750 Thr Thr Ala Cys Gly Cys Thr Ala Ala Gly Thr Cys Cys Cys Gly Thr 755 760 765 Ala Ala Gly Gly Ala Cys Ala Thr Cys Gly Gly Ala Gly Thr Gly Cys 770 775 780 Ala Gly Thr Cys Ala Cys Ala Cys Gly Thr Gly Thr Gly Gly Gly Thr 785 790 795 800 Cys Ala Gly Gly Gly Gly Ala Gly Gly Thr Thr Gly Cys Gly Ala Ala 805 810 815 Thr Cys Cys Gly Gly Thr Ala Gly Ala Thr Gly Cys Gly Ala Cys Cys 820 825 830 Gly Cys Thr Gly Cys Cys Ala Gly Ala Ala Gly Ala Ala Gly Ala Thr 835 840 845 Cys Cys Gly Thr Ala Thr Cys Thr Ala Cys Cys Ala Cys Thr Cys Cys 850 855 860 Cys Thr Gly Ala Cys Cys Gly Gly Ala Cys Thr Gly Cys Ala Cys Thr 865 870 875 880 Gly Cys Gly Thr Cys Thr Gly Gly Thr Gly Cys Cys Ala Cys Cys Thr 885 890 895 Gly Gly Ala Gly Ala Thr Cys Cys Ala Cys Gly Ala Cys Gly Ala Cys 900 905 910 Thr Gly Cys Cys Thr Gly Cys Ala Gly Gly Cys Cys Gly Thr Gly Gly 915 920 925 Gly Ala Cys Ala Cys Gly Ala Ala Thr Gly Cys Gly Ala Cys Thr Gly 930 935 940 Cys Gly Gly Thr Cys Thr Gly Cys Thr Gly Cys Gly Thr Gly Ala Cys 945 950 955 960 Cys Ala Cys Ala Thr Cys Cys Thr Gly Cys Cys Thr Cys Cys Cys Thr 965 970 975 Cys Cys Ala Gly Cys Ala Thr Cys Thr Ala Cys Cys Cys Thr Thr Cys 980 985 990 Ala Gly Thr Cys Cys Thr Gly Gly Cys Thr Thr Cys Cys Gly Gly Thr 995 1000 1005 Cys Cys Cys Gly Ala Cys Ala Gly Gly Ala Ala Gly Ala Ala Cys 1010 1015 1020 Ala Gly Cys Ala Ala Gly Ala Cys Cys Thr Cys Thr Cys Ala Gly 1025 1030 1035 Ala Ala Gly Ala Cys Thr Ala Thr Gly Gly Ala Cys Gly Ala Cys 1040 1045 1050 Cys Thr Gly Ala Ala Cys Cys Thr Gly Ala Gly Cys Ala Cys Cys 1055 1060 1065 Thr Cys Thr Gly Ala Gly Gly Cys Cys Cys Thr Gly Cys Gly Cys 1070 1075 1080 Ala Thr Cys Gly Ala Cys Cys Cys Thr Gly Thr Gly Cys Cys Cys 1085 1090 1095 Ala Ala Cys Ala Cys Thr Cys Ala Cys Cys Cys Ala Cys Thr Gly 1100 1105 1110 Cys Thr Gly Gly Thr Gly Thr Thr Cys Gly Thr Cys Ala Ala Cys 1115 1120 1125 Cys Cys Thr Ala Ala Gly Ala Gly Cys Gly Gly Cys Gly Gly Ala 1130 1135 1140 Ala Ala Gly Cys Ala Gly Gly Gly Thr Cys Ala Gly Ala Gly Ala 1145 1150 1155 Gly Thr Cys Cys Thr Gly Thr Gly Gly Ala Ala Gly Thr Thr Cys 1160 1165 1170 Cys Ala Gly Thr Ala Cys Ala Thr Cys Cys Thr Gly Ala Ala Cys 1175 1180 1185 Cys Cys Ala Cys Gly Cys Cys Ala Gly Gly Thr Gly Thr Thr Cys 1190 1195 1200 Ala Ala Cys Cys Thr Gly Cys Thr Gly Ala Ala Gly Gly Ala Cys 1205 1210 1215 Gly Gly Cys Cys Cys Thr Gly Ala Gly Ala Thr Cys Gly Gly Ala 1220 1225 1230 Cys Thr Gly Ala Gly Ala Cys Thr Gly Thr Thr Cys Ala Ala Gly 1235 1240 1245 Gly Ala Cys Gly Thr Gly Cys Cys Cys Gly Ala Cys Thr Cys Thr 1250 1255 1260 Cys Gly Cys Ala Thr Cys Cys Thr Cys Gly Thr Cys Thr Gly Cys 1265 1270 1275 Gly Gly Thr Gly Gly Cys Gly Ala Cys Gly Gly Thr Ala Cys Thr 1280 1285 1290 Gly Thr Gly Gly Gly Ala Thr Gly Gly Ala Thr Cys Cys Thr Gly 1295 1300 1305 Gly Ala Ala Ala Cys Thr Ala Thr Cys Gly Ala Cys Ala Ala Gly 1310 1315 1320 Gly Cys Thr Ala Ala Cys Cys Thr Gly Cys Cys Ala Gly Thr Gly 1325 1330 1335 Cys Thr Gly Cys Cys Ala Cys Cys Thr Gly Thr Gly Gly Cys Thr 1340 1345 1350 Gly Thr Cys Cys Thr Gly Cys Cys Ala Cys Thr Gly Gly Gly Ala 1355 1360 1365 Ala Cys Cys Gly Gly Thr Ala Ala Cys Gly Ala Cys Cys Thr Gly 1370 1375 1380 Gly Cys Thr Cys Gly Thr Thr Gly Cys Cys Thr Gly Cys Gly Thr 1385 1390 1395 Thr Gly Gly Gly Gly Ala Gly Gly Thr Gly Gly Cys Thr Ala Cys 1400 1405 1410 Gly Ala Gly Gly Gly Ala Cys Ala Gly Ala Ala Cys Cys Thr Gly 1415 1420 1425 Gly Cys Cys Ala Ala Gly Ala Thr Cys Cys Thr Gly Ala Ala Gly 1430 1435 1440 Gly Ala Cys Cys Thr Gly Gly Ala Ala Ala Thr Gly Ala Gly Cys 1445 1450 1455 Ala Ala Gly Gly Thr Gly Gly Thr Cys Cys Ala Cys Ala Thr Gly 1460 1465 1470 Gly Ala Cys Ala Gly Ala Thr Gly Gly Thr Cys Thr Gly Thr Gly 1475 1480 1485 Gly Ala Gly Gly Thr Cys Ala Thr Cys Cys Cys Ala Cys Ala Gly 1490 1495 1500 Cys Ala Gly Ala Cys Thr Gly Ala Gly Gly Ala Ala Ala Ala Gly 1505 1510 1515 Thr Cys Ala Gly Ala Cys Cys Cys Ala Gly Thr Cys Cys Cys Thr 1520 1525 1530 Thr Thr Cys Cys Ala Gly Ala Thr Cys Ala Thr Cys Ala Ala Cys 1535 1540 1545 Ala Ala Cys Thr Ala Cys Thr Thr Cys Ala Gly Cys Ala Thr Cys 1550 1555 1560 Gly Gly Thr Gly Thr Gly Gly Ala Cys Gly Cys Thr Thr Cys Thr 1565 1570 1575 Ala Thr Cys Gly Cys Cys Cys Ala Cys Ala Gly Ala Thr Thr Cys 1580 1585 1590 Cys Ala Cys Ala Thr Cys Ala Thr Gly Cys Gly Cys Gly Ala Gly 1595 1600 1605 Ala Ala Gly Thr Ala Cys Cys Cys Thr Gly Ala Ala Ala Ala Gly 1610 1615 1620 Thr Thr Cys Ala Ala Cys Thr Cys Cys Cys Gly Cys Ala Thr Gly 1625 1630 1635 Ala Ala Gly Ala Ala Cys Ala Ala Gly Cys Thr Gly Thr Gly Gly 1640 1645 1650 Thr Ala Cys Thr Thr Cys Gly Ala Gly Thr Thr Cys Gly Cys Thr 1655 1660 1665 Ala Cys Cys Thr Cys Ala Gly Ala Ala Thr Cys Cys Ala Thr Cys 1670 1675 1680 Thr Thr Cys Thr Cys Ala Ala Cys Thr Thr Gly Cys Ala Ala Gly 1685 1690 1695 Ala Ala Gly Cys Thr Gly Gly Ala Gly Gly Ala Ala Thr Cys Cys 1700 1705 1710 Cys Thr Gly Ala Cys Cys Gly Thr Cys Gly Ala Gly Ala Thr Cys 1715 1720 1725 Thr Gly Cys Gly Gly Cys Ala Ala Gly Cys Cys Thr Cys Thr Gly 1730 1735 1740 Gly Ala Cys Cys Thr Gly Thr Cys Ala Ala Ala Cys Cys Thr Gly 1745 1750 1755 Thr Cys Cys Cys Thr Gly Gly Ala Ala Gly Gly Cys Ala Thr Cys 1760 1765 1770 Gly Cys Thr Gly Thr Gly Cys Thr Gly Ala Ala Cys Ala Thr Cys 1775 1780 1785 Cys Cys Ala Ala Gly Cys Ala Thr Gly Cys Ala Cys Gly Gly Ala 1790 1795 1800 Gly Gly Thr Thr Cys Thr Ala Ala Cys Cys Thr Cys Thr Gly Gly 1805 1810 1815 Gly Gly Cys Gly Ala Cys Ala Cys Thr Ala Gly Gly Ala Gly Gly 1820 1825 1830 Cys Cys Thr Cys Ala Cys Gly Gly Thr Gly Ala Cys Ala Thr Cys 1835 1840 1845 Thr Ala Cys Gly Gly Cys Ala Thr Cys Ala Ala Cys Cys Ala Gly 1850 1855 1860 Gly Cys Cys Cys Thr Gly Gly Gly Ala Gly Cys Thr Ala Cys Cys 1865 1870 1875 Gly Cys Cys Ala Ala Gly Gly Thr Cys Ala Thr Cys Ala Cys Thr 1880 1885 1890 Gly Ala Cys Cys Cys Cys Gly Ala Cys Ala Thr Cys Cys Thr Gly 1895 1900 1905 Ala Ala Gly Ala Cys Cys Thr Gly Cys Gly Thr Gly Cys Cys Ala 1910 1915 1920 Gly Ala Cys Cys Thr Gly Ala Gly Cys Gly Ala Cys Ala Ala Gly 1925 1930 1935 Cys Gly Thr Cys Thr Gly Gly Ala Gly Gly Thr Gly Gly Thr Cys 1940 1945 1950 Gly Gly Ala Cys Thr Gly Gly Ala Gly Gly Gly Thr Gly Cys Cys 1955 1960 1965 Ala Thr Cys Gly Ala Ala Ala Thr Gly Gly Gly Cys Cys Ala Gly 1970 1975 1980 Ala Thr Cys Thr Ala Cys Ala Cys Thr Ala Ala Gly Cys Thr Gly 1985 1990 1995 Ala Ala Gly Ala Ala Cys Gly Cys Thr Gly Gly Ala Ala Gly Gly 2000 2005 2010 Ala Gly Ala Cys Thr Gly Gly Cys Cys Ala Ala Gly Thr Gly Cys 2015 2020 2025 Thr Cys Thr Gly Ala Gly Ala Thr Cys Ala Cys Cys Thr Thr Cys 2030 2035 2040 Cys Ala Cys Ala Cys Cys Ala Cys Thr Ala Ala Gly Ala Cys Thr 2045 2050 2055 Cys Thr Gly Cys Cys Thr Ala Thr Gly Cys Ala Gly Ala Thr Cys 2060 2065 2070 Gly Ala Cys Gly Gly Thr Gly Ala Ala Cys Cys Cys Thr Gly Gly 2075 2080 2085 Ala Thr Gly Cys Ala Gly Ala Cys Cys Cys Cys Ala Thr Gly Cys 2090 2095 2100 Ala Cys Thr Ala Thr Cys Ala Ala Gly Ala Thr Cys Ala Cys Cys 2105 2110 2115 Cys Ala Cys Ala Ala Gly Ala Ala Cys Cys Ala Gly Ala Thr Gly 2120 2125 2130 Cys Cys Cys Ala Thr Gly Cys Thr Gly Ala Thr Gly Gly Gly Thr 2135 2140 2145 Cys Cys Thr Cys Cys Thr Cys Cys Thr Cys Gly Cys Thr Cys Thr 2150 2155 2160 Gly Gly Ala Thr Cys Thr Thr Cys Ala Gly Ala Ala Ala Cys Thr 2165 2170 2175 Gly Thr Gly Ala Gly Gly Thr Thr Cys Cys Ala Gly Gly Gly Cys 2180 2185 2190 Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys Cys Ala Cys 2195 2200 2205 Cys Ala Cys Thr Gly Ala 2210 <210> 6 <211> 737 <212> PRT <213> Homo sapiens <400> 6 Met Ala Ser Pro Ser Asp Phe Ala Gln Leu Gln Lys Tyr Met Glu Tyr 1 5 10 15 Ser Thr Lys Lys Val Ser Asp Val Leu Lys Leu Phe Glu Asp Gly Glu 20 25 30 Met Ala Lys Tyr Val Gln Gly Asp Ala Ile Gly Tyr Glu Gly Phe Gln 35 40 45 Gln Phe Leu Lys Ile Tyr Leu Glu Val Asp Asn Val Pro Arg His Leu 50 55 60 Ser Leu Ala Leu Phe Gln Ser Phe Glu Thr Gly His Cys Leu Asn Glu 65 70 75 80 Thr Asn Val Thr Lys Asp Val Val Cys Leu Asn Asp Val Ser Cys Tyr 85 90 95 Phe Ser Leu Leu Glu Gly Gly Arg Pro Glu Asp Lys Leu Glu Phe Thr 100 105 110 Phe Lys Leu Tyr Asp Thr Asp Arg Asn Gly Ile Leu Asp Ser Ser Glu 115 120 125 Val Asp Lys Ile Ile Leu Gln Met Met Arg Val Ala Glu Tyr Leu Asp 130 135 140 Trp Asp Val Ser Glu Leu Arg Pro Ile Leu Gln Glu Met Met Lys Glu 145 150 155 160 Ile Asp Tyr Asp Gly Ser Gly Ser Val Ser Gln Ala Glu Trp Val Arg 165 170 175 Ala Gly Ala Thr Thr Val Pro Leu Leu Val Leu Leu Gly Leu Glu Met 180 185 190 Thr Leu Lys Asp Asp Gly Gln His Met Trp Arg Pro Lys Arg Phe Pro 195 200 205 Arg Pro Val Tyr Cys Asn Leu Cys Glu Ser Ser Ile Gly Leu Gly Lys 210 215 220 Gln Gly Leu Ser Cys Asn Leu Cys Lys Tyr Thr Val His Asp Gln Cys 225 230 235 240 Ala Met Lys Ala Leu Pro Cys Glu Val Ser Thr Tyr Ala Lys Ser Arg 245 250 255 Lys Asp Ile Gly Val Gln Ser His Val Trp Val Arg Gly Gly Cys Glu 260 265 270 Ser Gly Arg Cys Asp Arg Cys Gln Lys Lys Ile Arg Ile Tyr His Ser 275 280 285 Leu Thr Gly Leu His Cys Val Trp Cys His Leu Glu Ile His Asp Asp 290 295 300 Cys Leu Gln Ala Val Gly His Glu Cys Asp Cys Gly Leu Leu Arg Asp 305 310 315 320 His Ile Leu Pro Pro Ser Ser Ile Tyr Pro Ser Val Leu Ala Ser Gly 325 330 335 Pro Asp Arg Lys Asn Ser Lys Thr Ser Gln Lys Thr Met Asp Asp Leu 340 345 350 Asn Leu Ser Thr Ser Glu Ala Leu Arg Ile Asp Pro Val Pro Asn Thr 355 360 365 His Pro Leu Leu Val Phe Val Asn Pro Lys Ser Gly Gly Lys Gln Gly 370 375 380 Gln Arg Val Leu Trp Lys Phe Gln Tyr Ile Leu Asn Pro Arg Gln Val 385 390 395 400 Phe Asn Leu Leu Lys Asp Gly Pro Glu Ile Gly Leu Arg Leu Phe Lys 405 410 415 Asp Val Pro Asp Ser Arg Ile Leu Val Cys Gly Gly Asp Gly Thr Val 420 425 430 Gly Trp Ile Leu Glu Thr Ile Asp Lys Ala Asn Leu Pro Val Leu Pro 435 440 445 Pro Val Ala Val Leu Pro Leu Gly Thr Gly Asn Asp Leu Ala Arg Cys 450 455 460 Leu Arg Trp Gly Gly Gly Tyr Glu Gly Gln Asn Leu Ala Lys Ile Leu 465 470 475 480 Lys Asp Leu Glu Met Ser Lys Val Val His Met Asp Arg Trp Ser Val 485 490 495 Glu Val Ile Pro Gln Gln Thr Glu Glu Lys Ser Asp Pro Val Pro Phe 500 505 510 Gln Ile Ile Asn Asn Tyr Phe Ser Ile Gly Val Asp Ala Ser Ile Ala 515 520 525 His Arg Phe His Ile Met Arg Glu Lys Tyr Pro Glu Lys Phe Asn Ser 530 535 540 Arg Met Lys Asn Lys Leu Trp Tyr Phe Glu Phe Ala Thr Ser Glu Ser 545 550 555 560 Ile Phe Ser Thr Cys Lys Lys Leu Glu Glu Ser Leu Thr Val Glu Ile 565 570 575 Cys Gly Lys Pro Leu Asp Leu Ser Asn Leu Ser Leu Glu Gly Ile Ala 580 585 590 Val Leu Asn Ile Pro Ser Met His Gly Gly Ser Asn Leu Trp Gly Asp 595 600 605 Thr Arg Arg Pro His Gly Asp Ile Tyr Gly Ile Asn Gln Ala Leu Gly 610 615 620 Ala Thr Ala Lys Val Ile Thr Asp Pro Asp Ile Leu Lys Thr Cys Val 625 630 635 640 Pro Asp Leu Ser Asp Lys Arg Leu Glu Val Val Gly Leu Glu Gly Ala 645 650 655 Ile Glu Met Gly Gln Ile Tyr Thr Lys Leu Lys Asn Ala Gly Arg Arg 660 665 670 Leu Ala Lys Cys Ser Glu Ile Thr Phe His Thr Thr Lys Thr Leu Pro 675 680 685 Met Gln Ile Asp Gly Glu Pro Trp Met Gln Thr Pro Cys Thr Ile Lys 690 695 700 Ile Thr His Lys Asn Gln Met Pro Met Leu Met Gly Pro Pro Pro Arg 705 710 715 720 Ser Gly Ser Ser Glu Thr Val Arg Phe Gln Gly His His His His His 725 730 735 His

Claims

1. A compound or a salt thereof, wherein the compound has the following structure: in: R1 is F, -CN or -OCH3; R2 is H, -CH3, -CH2CN, -CH2CH2F or -CH2CH=CH2; R4 is -CH2R 4a or -CHR 4a R 4b ; R 4a is phenyl, naphthyl or indolyl, each substituted with zero to 2 substituents independently selected from the group consisting of F, -CH3, -CH2CH3 and -OCH3; R 4b is phenyl or fluorophenyl; R 5a and R 5c independently selected from R5; each R5 is -CH3; and m is zero, 1 or 2.

2. The compound or salt thereof according to claim 1, wherein the compound has the following structure:

3. A pharmaceutical composition comprising the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable carrier.

4. Use of the compound according to any one of claims 1 to 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating cancer or viral infection.

5. The use according to claim 4, wherein the cancer is selected from colon cancer, pancreatic cancer, breast cancer, prostate cancer, lung cancer, ovarian cancer, cervical cancer, kidney cancer, head and neck cancer, lymphoma, leukemia and melanoma.

Citation Information

Patent Citations

  • Anti-ox40l antibodies

    WO2006029879A2

  • Human monoclonal antibodies to programmed death ligand 1 (PD-l1)

    WO2007005874A2

  • N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

    WO2007075598A2

  • N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

    WO2008036642A2

  • N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase

    WO2008036653A2